"id_redcap","id_covidence","article","virus","covid","rsv","flu","population","preg","infant","child","adult","elder","immunocomp","rob","study_design","published_year","journal","pmid","pmcid","doi","link","title"
1,"#9075","Otsuki 2024","RSV",0,1,0,"Pediatric",1,1,0,0,0,0,"Low","RCT",2024,"Vaccine",38853036,,"10.1016/j.vaccine.2024.06.009","https://pubmed.ncbi.nlm.nih.gov/38853036","Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial"
1,"#9075","Otsuki 2024","RSV",0,1,0,"Pregnant",1,1,0,0,0,0,"Low","RCT",2024,"Vaccine",38853036,,"10.1016/j.vaccine.2024.06.009","https://pubmed.ncbi.nlm.nih.gov/38853036","Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial"
2,"#3443","Simoes 2025","RSV",0,1,0,"Pregnant",1,0,0,0,0,0,"Low","RCT",2025,"Obstet Gynecol",39746212,,"10.1097/aog.0000000000005816","https://pubmed.ncbi.nlm.nih.gov/39746212","Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial"
4,"#6167","Fell 2024","Influenza",0,0,1,"Pediatric",0,1,0,0,0,0,"Low","Case-control",2024,"J Infect Dis",39052720,"PMC11272077","10.1093/infdis/jiad539","https://pmc.ncbi.nlm.nih.gov/articles/PMC11272077","Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada"
5,"#21721","Gentile 2025","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"Low","Case-control",2025,"Pediatr Infect Dis J",40440704,,"10.1097/inf.0000000000004878","https://pubmed.ncbi.nlm.nih.gov/40440704","Maternal Immunization With RSVpreF Vaccine: Effectiveness in Preventing Respiratory Syncytial Virus-associated Hospitalizations in Infants Under 6 Months in Argentina: Multicenter Case-control Study"
6,"#1471","Hall 2025","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2025,"Vaccine",39970594,,"10.1016/j.vaccine.2025.126894","https://pubmed.ncbi.nlm.nih.gov/39970594","COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021"
7,"#6794","Havers 2024","COVID",1,0,0,"Pediatric",0,1,0,0,0,0,"Low","Observational - other",2024,"MMWR Morb Mortal Wkly Rep",39325677,"PMC11563568","10.15585/mmwr.mm7338a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11563568","COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months - COVID-NET, 12 States, October 2022-April 2024"
8,"#6950","Hsiao 2024","Influenza",0,0,1,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2024,"AJOG Global Reports",39512761,"PMC11541679","10.1016/j.xagr.2024.100395","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541679","Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants"
10,"_#2063","Lee 2025","Influenza",0,0,1,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2025,"Clin Pharmacol Ther",39854110,,"10.1002/cpt.3565","https://pubmed.ncbi.nlm.nih.gov/39854110","Association of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population-Based Cohort Study"
11,"#9276","Perez-Gimeno 2024","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Low","Case-control",2024,"Euro Surveill",39364601,,"10.2807/1560-7917.Es.2024.29.40.2400618","https://pubmed.ncbi.nlm.nih.gov/39364601","Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24"
12,"#23773","Perez Marc 2025","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"Low","Case-control",2025,"Lancet Infect Dis",40339585,,"10.1016/s1473-3099(25)00156-2","https://pubmed.ncbi.nlm.nih.gov/40339585","Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study"
13,"#10470","Tamir-Hostovsky 2024","COVID",1,0,0,"Pediatric",0,1,0,0,0,0,"Low","Case-control",2024,"Acta Paediatr",38923614,,"10.1111/apa.17329","https://pubmed.ncbi.nlm.nih.gov/38923614","Association of BNT162b2 SARS-CoV-2 vaccination during pregnancy with postnatal outcomes in premature infants"
14,"#3965","Williams 2025","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"Low","Case-control",2025,"Lancet Child Adolesc Health",40690922,,"10.1016/S2352-4642(25)00155-5","https://pubmed.ncbi.nlm.nih.gov/40690922","Bivalent Prefusion F Vaccination in Pregnancy and Respiratory Syncytial Virus Hospitalisation in Infants: Results of a Prospective, Multi-Centre, Test-Negative Study"
15,"#4454","Al-Haddad 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Health Science Reports",38784253,"PMC11112633","10.1002/hsr2.2142","https://pmc.ncbi.nlm.nih.gov/articles/PMC11112633","The impact of SARS-CoV-2 mRNA vaccine on intracytoplasmic sperm injection outcomes at a fertility center in Iraq: A prospective cohort study"
16,"_#116","Alami 2025","RSV",0,1,0,"Pregnant",1,0,0,0,0,0,"High","Observational - other",2025,"BMJ Open",40187782,"PMC11973799","10.1136/bmjopen-2024-087850","https://pmc.ncbi.nlm.nih.gov/articles/PMC11973799","Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System"
18,"#5488","Choi 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2024,"Eur Heart J",38993069,,"10.1093/eurheartj/ehae335","https://pubmed.ncbi.nlm.nih.gov/38993069","Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study"
18,"#5488","Choi 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2024,"Eur Heart J",38993069,,"10.1093/eurheartj/ehae335","https://pubmed.ncbi.nlm.nih.gov/38993069","Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study"
19,"#782","Choi 2025","Influenza",0,0,1,"Pregnant",1,0,0,0,0,0,"High","Observational - other",2025,"Vaccine",39591703,,"10.1016/j.vaccine.2024.126506","https://pubmed.ncbi.nlm.nih.gov/39591703","The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination"
20,"#5806","Denoble 2024","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"Low","Case-control",2024,"Obstet Gynecol",38843526,,"10.1097/aog.0000000000005632","https://pubmed.ncbi.nlm.nih.gov/38843526","Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink"
21,"#6443","Getahun 2024","Influenza",0,0,1,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2024,"JAMA Netw Open",39298167,"PMC11413712","10.1001/jamanetworkopen.2024.34857","https://pmc.ncbi.nlm.nih.gov/articles/PMC11413712","Safety of the Seasonal Influenza Vaccine in 2 Successive Pregnancies"
22,"#15755","Jorgensen 2024","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2024,"BMJ Med",39574424,"PMC11579536","10.1136/bmjmed-2023-000743","https://pmc.ncbi.nlm.nih.gov/articles/PMC11579536","Association between maternal mRNA covid-19 vaccination in early pregnancy and major congenital anomalies in offspring: population based cohort study with sibling matched analysis"
24,"#2008","Lacroix 2025","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"High","Observational - other",2025,"Therapie",38997859,,"10.1016/j.therap.2024.06.003","https://pubmed.ncbi.nlm.nih.gov/38997859","COVACPREG, a French prospective cohort study of women vaccinated against COVID-19 during pregnancy"
25,"#16358","Lee 2024","COVID",1,0,1,"Pediatric",1,1,1,1,1,0,"High","Observational - other",2024,"J Med Virol",38859751,,"10.1002/jmv.29693","https://pubmed.ncbi.nlm.nih.gov/38859751","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database"
25,"#16358","Lee 2024","Influenza",1,0,1,"Pediatric",1,1,1,1,1,0,"High","Observational - other",2024,"J Med Virol",38859751,,"10.1002/jmv.29693","https://pubmed.ncbi.nlm.nih.gov/38859751","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database"
25,"#16358","Lee 2024","COVID",1,0,1,"Adult",1,1,1,1,1,0,"High","Observational - other",2024,"J Med Virol",38859751,,"10.1002/jmv.29693","https://pubmed.ncbi.nlm.nih.gov/38859751","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database"
25,"#16358","Lee 2024","Influenza",1,0,1,"Adult",1,1,1,1,1,0,"High","Observational - other",2024,"J Med Virol",38859751,,"10.1002/jmv.29693","https://pubmed.ncbi.nlm.nih.gov/38859751","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database"
25,"#16358","Lee 2024","COVID",1,0,1,"Pregnant",1,1,1,1,1,0,"High","Observational - other",2024,"J Med Virol",38859751,,"10.1002/jmv.29693","https://pubmed.ncbi.nlm.nih.gov/38859751","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database"
25,"#16358","Lee 2024","Influenza",1,0,1,"Pregnant",1,1,1,1,1,0,"High","Observational - other",2024,"J Med Virol",38859751,,"10.1002/jmv.29693","https://pubmed.ncbi.nlm.nih.gov/38859751","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database"
26,"#8321","Magnus 2024","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2024,"Am J Obstet Gynecol",38697336,,"10.1016/j.ajog.2024.04.028","https://pubmed.ncbi.nlm.nih.gov/38697336","COVID-19 vaccination during pregnancy is not associated with an increased risk of severe postpartum hemorrhage"
27,"#2339","Malange 2025","Influenza",0,0,1,"Pregnant",1,0,0,0,0,0,"Low","Case-control",2025,"Vaccine",40418866,,"10.1016/j.vaccine.2025.127297","https://pubmed.ncbi.nlm.nih.gov/40418866","Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019"
28,"#8569","Mensah 2024","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"Low","Case-control",2024,"Bjog",39279662,,"10.1111/1471-0528.17949","https://pubmed.ncbi.nlm.nih.gov/39279662","COVID-19 Vaccine Safety in Pregnancy, A Nested Case-Control Study in Births From April 2021 to March 2022, England"
29,"#8588","Metz 2024","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2024,"Obstet Gynecol",38991216,,"10.1097/aog.0000000000005670","https://pubmed.ncbi.nlm.nih.gov/38991216","Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy"
30,"#9547","Regan 2023","Influenza",0,0,1,"Pregnant",1,0,0,0,0,0,"Moderate","Cohort",2023,"Obstet Gynecol",37535959,,"10.1097/aog.0000000000005279","https://pubmed.ncbi.nlm.nih.gov/37535959","Risk of Miscarriage in Relation to Seasonal Influenza Vaccination Before or During Pregnancy"
31,"#9546","Regan 2024","Influenza",0,0,1,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2024,"Vaccine",39260053,"PMC11911014","10.1016/j.vaccine.2024.126256","https://pmc.ncbi.nlm.nih.gov/articles/PMC11911014","Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study"
34,"#3394","Sheth 2025","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"Low","Case-control",2025,"Obstet Gynecol",40311142,,"10.1097/aog.0000000000005904","https://pubmed.ncbi.nlm.nih.gov/40311142","Coronavirus Disease 2019 (COVID-19) Vaccination and Spontaneous Abortion"
35,"#10424","Suseeladevi 2024","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2024,"The Lancet Regional Health - Europe",39974773,"PMC11838104","10.1016/j.lanepe.2024.101025","https://pmc.ncbi.nlm.nih.gov/articles/PMC11838104","COVID-19 vaccination and birth outcomes of 186,990 women vaccinated before pregnancy: an England-wide cohort study"
37,"#3980","Woestenberg 2025","COVID",1,0,0,"Pregnant",1,0,0,0,0,0,"High","Cohort",2025,"Birth Defects Res",40476384,"PMC12142568","10.1002/bdr2.2490","https://pmc.ncbi.nlm.nih.gov/articles/PMC12142568","Comparison of Perceived Adverse Events After COVID-19 Vaccination Between Pregnant and NonPregnant Women Using Two Cohort Studies in the Netherlands"
38,"#4651","Arbetter 2024","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Moderate","RCT",2024,"Clin Infect Dis",39656748,,"10.1093/cid/ciae596","https://pubmed.ncbi.nlm.nih.gov/39656748","Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)"
39,"#5870","Dixit 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Lancet Infect Dis",38518789,,"10.1016/s1473-3099(24)00101-4","https://pubmed.ncbi.nlm.nih.gov/38518789","Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial"
40,"#21593","Folegatti 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,0,0,"High","Observational - other",2025,"Lancet Infect Dis",40412421,,"10.1016/s1473-3099(25)00153-7","https://pubmed.ncbi.nlm.nih.gov/40412421","Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study"
40,"#21593","Folegatti 2025","Influenza",0,0,1,"Adult",0,0,1,1,0,0,"High","Observational - other",2025,"Lancet Infect Dis",40412421,,"10.1016/s1473-3099(25)00153-7","https://pubmed.ncbi.nlm.nih.gov/40412421","Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study"
41,"#1605","Huang 2025","Influenza",0,0,1,"Pediatric",0,1,1,0,0,0,"Low","RCT",2025,"Vaccines",40432079,"PMC12116156","10.3390/vaccines13050467","https://pmc.ncbi.nlm.nih.gov/articles/PMC12116156","The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 635 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial"
42,"#7666","Kothari 2024","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Low","RCT",2024,"Hum Vaccin Immunother",39445787,"PMC11508945","10.1080/21645515.2024.2416329","https://pmc.ncbi.nlm.nih.gov/articles/PMC11508945","A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months"
43,"#2376","Mao 2025","RSV",0,1,0,"Adult",0,0,0,1,0,0,"High","RCT",2025,"Clin Transl Sci",39736101,"PMC11684469","10.1111/cts.70095","https://pmc.ncbi.nlm.nih.gov/articles/PMC11684469","A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults"
44,"#2631","Munro 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","RCT",2025,"Lancet Child Adolesc Health",40379431,,"10.1016/s2352-4642(25)00102-6","https://pubmed.ncbi.nlm.nih.gov/40379431","180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial"
45,"#2667","Nakayama 2025","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Low","RCT",2025,"J Infect Chemother",38959995,,"10.1016/j.jiac.2024.06.023","https://pubmed.ncbi.nlm.nih.gov/38959995","The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study"
46,"#10945","Wang 2024","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Moderate","RCT",2024,"Hum Vaccin Immunother",39540202,"PMC11572236","10.1080/21645515.2024.2425149","https://pmc.ncbi.nlm.nih.gov/articles/PMC11572236","Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6-35 months of age in China: A randomized, double-blind, clinical trial"
47,"#428","Bennett 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"Low","RCT",2025,"J Infect",39874991,,"10.1016/j.jinf.2025.106428","https://pubmed.ncbi.nlm.nih.gov/39874991","Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial"
49,"#4486","Alejandre 2024","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"High","Observational - other",2024,"Eur J Pediatr",38910199,,"10.1007/s00431-024-05634-z","https://pubmed.ncbi.nlm.nih.gov/38910199","Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care"
50,"#20369","Andersen 2025","COVID",1,1,1,"Pediatric",0,1,1,0,0,0,"Moderate","Cohort",2025,"Pediatr Infect Dis J",40440707,,"10.1097/inf.0000000000004866","https://pubmed.ncbi.nlm.nih.gov/40440707","Clinical Outcomes in Children <5 Years of Age Hospitalized for Respiratory Syncytial Virus, COVID-19 or Influenza in the United States"
50,"#20369","Andersen 2025","RSV",1,1,1,"Pediatric",0,1,1,0,0,0,"Moderate","Cohort",2025,"Pediatr Infect Dis J",40440707,,"10.1097/inf.0000000000004866","https://pubmed.ncbi.nlm.nih.gov/40440707","Clinical Outcomes in Children <5 Years of Age Hospitalized for Respiratory Syncytial Virus, COVID-19 or Influenza in the United States"
50,"#20369","Andersen 2025","Influenza",1,1,1,"Pediatric",0,1,1,0,0,0,"Moderate","Cohort",2025,"Pediatr Infect Dis J",40440707,,"10.1097/inf.0000000000004866","https://pubmed.ncbi.nlm.nih.gov/40440707","Clinical Outcomes in Children <5 Years of Age Hospitalized for Respiratory Syncytial Virus, COVID-19 or Influenza in the United States"
51,"#13170","Ares-Gomez 2024","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","Cohort",2024,"Lancet Infect Dis",38701823,,"10.1016/s1473-3099(24)00215-9","https://pubmed.ncbi.nlm.nih.gov/38701823","Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study"
52,"#4837","Barbas Del Buey 2024","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"Low","Cohort",2024,"Front Public Health",39220460,"PMC11361977","10.3389/fpubh.2024.1441786","https://pmc.ncbi.nlm.nih.gov/articles/PMC11361977","The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study"
53,"#4960","Berthaud 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Clin Infect Dis",39158584,"PMC11650855","10.1093/cid/ciae420","https://pmc.ncbi.nlm.nih.gov/articles/PMC11650855","Safety and Immunogenicity of an mRNA-1273 Booster in Children"
57,"#5255","Carbajal 2024","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","Case-control",2024,"Lancet Child Adolesc Health",39208832,,"10.1016/s2352-4642(24)00171-8","https://pubmed.ncbi.nlm.nih.gov/39208832","Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France"
58,"#633","Carcione 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"High","Observational - other",2025,"Pediatr Infect Dis J",39773919,,"10.1097/inf.0000000000004715","https://pubmed.ncbi.nlm.nih.gov/39773919","ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024"
59,"#5520","Churilla 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Pediatr Transplant",38766983,,"10.1111/petr.14786","https://pubmed.ncbi.nlm.nih.gov/38766983","Safety and infectious outcomes in pediatric kidney transplant recipients after COVID-19 vaccination: A pediatric nephrology research consortium study"
60,"#5560","Coma 2024","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"Low","Cohort",2024,"Arch Dis Child",38857952,"PMC11347209","10.1136/archdischild-2024-327153","https://pmc.ncbi.nlm.nih.gov/articles/PMC11347209","Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)"
61,"#28053","Copland 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"Low","Observational - other",2024,"Nat Commun",38802362,"PMC11130197","10.1038/s41467-024-47745-z","https://pmc.ncbi.nlm.nih.gov/articles/PMC11130197","Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England"
62,"#21167","Dammann 2025","Influenza",0,0,1,"Pediatric",0,1,1,0,0,0,"Low","Cohort",2025,"Vaccines (Basel)",39852821,"PMC11769184","10.3390/vaccines13010042","https://pmc.ncbi.nlm.nih.gov/articles/PMC11769184","Influenza Immunization in Very-Low-Birth-Weight Infants: Epidemiology and Long-Term Outcomes"
63,"#5883","Domachowske 2024","RSV",0,1,0,"Immunocomp",0,1,1,0,0,1,"High","Observational - other",2024,"Pediatrics",39257380,,"10.1542/peds.2024-066508","https://pubmed.ncbi.nlm.nih.gov/39257380","Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children"
64,"#6030","El Hilali 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Clinical Epidemiology and Global Health",,,"10.1016/j.cegh.2024.101689","https://doi.org/10.1016/j.cegh.2024.101689","Adverse effects of COVID-19 vaccines in the Moroccan adults and children during the pandemic"
64,"#6030","El Hilali 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Clinical Epidemiology and Global Health",,,"10.1016/j.cegh.2024.101689","https://doi.org/10.1016/j.cegh.2024.101689","Adverse effects of COVID-19 vaccines in the Moroccan adults and children during the pandemic"
65,"#1130","Estrella-Porter 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"High","Observational - other",2025,"Vaccines (Basel)",40573954,"PMC12197746","10.3390/vaccines13060623","https://pmc.ncbi.nlm.nih.gov/articles/PMC12197746","Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain's 2023-2024 RSV Immunisation Campaign"
66,"#1181","Fazal 2025","Influenza",0,0,1,"Pediatric",0,1,1,0,0,0,"Moderate","Observational - other",2025,"MMWR Morb Mortal Wkly Rep",40014654,"PMC11867584","10.15585/mmwr.mm7406a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867584","Reports of Encephalopathy Among Children with Influenza-Associated Mortality - United States, 2010-11 Through 2024-25 Influenza Seasons"
67,"#1407","Grieshaber 2025","COVID",1,0,0,"Pediatric",0,1,1,0,0,0,"Moderate","Observational - other",2025,"Dtsch Arztebl Int",40101263,,"10.3238/arztebl.m2025.0032","https://pubmed.ncbi.nlm.nih.gov/40101263","The Long-Term Tolerability of BNT162b2 in Children and Adolescents (the CoVacU18 Study)"
68,"#1574","Holzwarth 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"Infection",39527343,"PMC11971181","10.1007/s15010-024-02427-2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11971181","PaedVacCOVID - safety of the BNT162b2 vaccine against the SARS-CoV-2 in children with and without comorbidities aged 5 to 11 years"
69,"#1900","Kim 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"Low","Observational - other",2025,"J Korean Med Sci",39834222,"PMC11745927","10.3346/jkms.2025.40.e10","https://pmc.ncbi.nlm.nih.gov/articles/PMC11745927","Risk of Kawasaki Disease/Multisystem Inflammatory Syndrome Following COVID-19 Vaccination in Korean Children: A Self-Controlled Case Series Study"
70,"#7737","Kurucu 2024","COVID",1,0,0,"Immunocomp",0,0,1,1,0,1,"High","Observational - other",2024,"Turk J Pediatr",39387432,,"10.24953/turkjpediatr.2024.4512","https://pubmed.ncbi.nlm.nih.gov/39387432","Safety and efficacy of COVID-19 vaccines in children and adolescents with cancer"
72,"#7891","Lee 2024","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Low","Case-control",2024,"VACCINE: X",39886534,"PMC11780392","10.1016/j.jvacx.2024.100570","https://pmc.ncbi.nlm.nih.gov/articles/PMC11780392","Influenza vaccine effectiveness against influenza-associated hospitalizations in children, Hong Kong, November 2023 to June 2024"
73,"#2068","Lee 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"Low","Cohort",2025,"PAEDIATRICS & CHILD HEALTH",40756534,"PMC12316524","10.1093/pch/pxae101","https://pmc.ncbi.nlm.nih.gov/articles/PMC12316524","Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: A population-based study"
74,"#7907","Lefferts 2024","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","Case-control",2024,"MMWR Morb Mortal Wkly Rep",39541241,"PMC11576050","10.15585/mmwr.mm7345a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11576050","Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024"
75,"#8011","Li 2024","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Vaccines",38543956,"PMC10975893","10.3390/vaccines12030321","https://pmc.ncbi.nlm.nih.gov/articles/PMC10975893","Exploratory Study of the Phase IV Immunization Schedule of Quadrivalent Influenza Split-Virion Vaccine in Children Aged 38 Years"
76,"#22825","Lim 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"J Allergy Clin Immunol Glob",39844915,"PMC11750530","10.1016/j.jacig.2024.100387","https://pmc.ncbi.nlm.nih.gov/articles/PMC11750530","Outcomes of pediatric patients with suspected allergies to COVID-19 vaccines"
77,"#2222","Liu 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"Expert Opin Drug Saf",38666296,,"10.1080/14740338.2024.2348568","https://pubmed.ncbi.nlm.nih.gov/38666296","Analysis of new-onset seizures following use of COVID-19 vaccinations in children based on VAERS"
78,"#16794","Madni 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"JAMA Netw Open",39585698,"PMC11589793","10.1001/jamanetworkopen.2024.47492","https://pmc.ncbi.nlm.nih.gov/articles/PMC11589793","COVID-19 Vaccine Reactogenicity Among Young Children"
79,"#11770","Marouk 2025","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"High","Observational - other",2025,"Eur J Pediatr",40044918,,"10.1007/s00431-025-06050-7","https://pubmed.ncbi.nlm.nih.gov/40044918","Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3months: a retrospective study"
81,"#2559","Moline 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Moderate","Case-control",2025,"JAMA Pediatr",39652359,"PMC11667569","10.1001/jamapediatrics.2024.5572","https://pmc.ncbi.nlm.nih.gov/articles/PMC11667569","Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024"
82,"#8693","Moor 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Biol Sex Differ",39327617,"PMC11426002","10.1186/s13293-024-00651-x","https://pmc.ncbi.nlm.nih.gov/articles/PMC11426002","Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study"
83,"#2751","Nunez 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","Case-control",2025,"Euro Surveill",39916606,,"10.2807/1560-7917.Es.2025.30.5.2400596","https://pubmed.ncbi.nlm.nih.gov/39916606","Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season"
85,"#2768","Ocana de Sentuary 2025","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"High","Observational - other",2025,"eClinicalMedicine",39726670,"PMC11669793","10.1016/j.eclinm.2024.102986","https://pmc.ncbi.nlm.nih.gov/articles/PMC11669793","Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France"
87,"#2916","Patton 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","Observational - other",2025,"MMWR Morb Mortal Wkly Rep",40338822,"PMC12061057","10.15585/mmwr.mm7416a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC12061057","Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025"
88,"#2957","Perramon-Malavez 2025","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"Low","Cohort",2025,"Pediatr Infect Dis J",39823640,,"10.1097/inf.0000000000004672","https://pubmed.ncbi.nlm.nih.gov/39823640","Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-related Outcomes in Hospital Care Settings: A Seasonal Cohort Study of Infants in Catalonia, Spain"
89,"#2956","Perramon-Malavez 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","Observational - other",2025,"The Lancet Regional Health - Europe",40950943,"PMC12426819","10.1016/j.lanepe.2025.101334","https://pmc.ncbi.nlm.nih.gov/articles/PMC12426819","Real-world impact of nirsevimab immunisation against respiratory disease on emergency department attendances and admissions among infants: a multinational retrospective analysis"
90,"#9295","Pham-Huy 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Vaccine",39003104,,"10.1016/j.vaccine.2024.06.057","https://pubmed.ncbi.nlm.nih.gov/39003104","Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center"
92,"#23868","Prasertsakul 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Case-control",2025,"Children (Basel)",40564636,"PMC12190996","10.3390/children12060678","https://pmc.ncbi.nlm.nih.gov/articles/PMC12190996","Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study"
94,"#3135","Rigamonti 2025","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Low","Cohort",2025,"Vaccine",40023131,,"10.1016/j.vaccine.2025.126946","https://pubmed.ncbi.nlm.nih.gov/40023131","Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children"
95,"#3137","Rius-Peris 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Moderate","Observational - other",2025,"Acta Paediatr",40135713,,"10.1111/apa.70066","https://pubmed.ncbi.nlm.nih.gov/40135713","Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus-Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns"
97,"#10102","Shi 2023","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Moderate","RCT",2023,"Vaccines",37896989,"PMC10611167","10.3390/vaccines11101586","https://pmc.ncbi.nlm.nih.gov/articles/PMC10611167","Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 38 Years"
98,"#10114","Shinjoh 2024","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Low","Case-control",2024,"Vaccine",39178768,,"10.1016/j.vaccine.2024.126241","https://pubmed.ncbi.nlm.nih.gov/39178768","Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures"
99,"#24371","Shinjoh 2025","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Low","Case-control",2025,"Vaccine",40578174,,"10.1016/j.vaccine.2025.127429","https://pubmed.ncbi.nlm.nih.gov/40578174","Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated vaccine and limited use of newly introduced live-attenuated vaccine"
100,"#18764","Soe 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Cohort",2024,"Lancet Reg Health Am",39659558,"PMC11629564","10.1016/j.lana.2024.100949","https://pmc.ncbi.nlm.nih.gov/articles/PMC11629564","mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study"
101,"#19017","Tartof 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"Low","Case-control",2024,"JAMA Netw Open",39666343,"PMC11638790","10.1001/jamanetworkopen.2024.49944","https://pmc.ncbi.nlm.nih.gov/articles/PMC11638790","BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age"
102,"#19044","Tenforde 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2024,"Clin Infect Dis",39656838,"PMC12287760","10.1093/cid/ciae597","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287760","Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States"
102,"#19044","Tenforde 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2024,"Clin Infect Dis",39656838,"PMC12287760","10.1093/cid/ciae597","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287760","Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States"
103,"#24752","Top 2025","COVID",1,0,0,"Pediatric",0,1,1,0,0,0,"Low","Observational - other",2025,"J Pediatr",40373954,,"10.1016/j.jpeds.2025.114642","https://pubmed.ncbi.nlm.nih.gov/40373954","Active Surveillance for Myocarditis and Pericarditis in Canadian Children from 2021 to 2022: A Canadian Immunization Monitoring Program ACTive Study"
104,"#3727","Torres 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","Cohort",2025,"Lancet Infect Dis",40513593,,"10.1016/s1473-3099(25)00233-6","https://pubmed.ncbi.nlm.nih.gov/40513593","Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study"
105,"#3948","Wen 2025","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"Hum Vaccin Immunother",39993940,"PMC11853548","10.1080/21645515.2025.2468074","https://pmc.ncbi.nlm.nih.gov/articles/PMC11853548","Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3-8 years with or without previous influenza vaccination histories"
106,"#25149","Wu 2025","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"Low","Cohort",2025,"EClinicalMedicine",39720603,"PMC11667630","10.1016/j.eclinm.2024.102962","https://pmc.ncbi.nlm.nih.gov/articles/PMC11667630","Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents"
106,"#25149","Wu 2025","COVID",1,0,0,"Adult",0,0,1,1,0,0,"Low","Cohort",2025,"EClinicalMedicine",39720603,"PMC11667630","10.1016/j.eclinm.2024.102962","https://pmc.ncbi.nlm.nih.gov/articles/PMC11667630","Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents"
107,"#4131","Yousaf 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"Low","Case-control",2025,"JAMA Netw Open",39992656,"PMC11851240","10.1001/jamanetworkopen.2024.59672","https://pmc.ncbi.nlm.nih.gov/articles/PMC11851240","COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years"
109,"#4409","Ahn 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"Moderate","Cohort",2024,"J Korean Med Sci",39716863,"PMC11666327","10.3346/jkms.2024.39.e317","https://pmc.ncbi.nlm.nih.gov/articles/PMC11666327","Epidemiological Characteristics and Outcome of Myocarditis and Pericarditis Temporally Associated With BNT162b2 COVID-19 Vaccine in Adolescents: Korean National Surveillance"
111,"#13386","Bea 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2024,"J Clin Endocrinol Metab",39657695,,"10.1210/clinem/dgae858","https://pubmed.ncbi.nlm.nih.gov/39657695","The Impact of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients"
111,"#13386","Bea 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2024,"J Clin Endocrinol Metab",39657695,,"10.1210/clinem/dgae858","https://pubmed.ncbi.nlm.nih.gov/39657695","The Impact of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients"
112,"#6208","Figueroa 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"eClinicalMedicine",39091673,"PMC11293523","10.1016/j.eclinm.2024.102720","https://pmc.ncbi.nlm.nih.gov/articles/PMC11293523","Safety and durability of mRNA-1273induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial"
113,"#1212","Figueroa 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"Lancet Infect Dis",39332418,,"10.1016/s1473-3099(24)00501-2","https://pubmed.ncbi.nlm.nih.gov/39332418","Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial"
114,"#1210","Figueroa 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"Hum Vaccin Immunother",39836458,,"10.1080/21645515.2024.2436714","https://pubmed.ncbi.nlm.nih.gov/39836458","Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents"
115,"#6236","Fitzpatrick 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Vaccine",38910092,,"10.1016/j.vaccine.2024.06.045","https://pubmed.ncbi.nlm.nih.gov/38910092","Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study"
116,"#7598","Ko 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Osong Public Health and Research Perspectives",38988090,"PMC11391368","10.24171/j.phrp.2024.0081","https://pmc.ncbi.nlm.nih.gov/articles/PMC11391368","Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea"
119,"#3691","Thepveera 2025","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"Lupus",40156281,,"10.1177/09612033251331244","https://pubmed.ncbi.nlm.nih.gov/40156281","Disease exacerbation and COVID-19 following mRNA COVID-19 vaccination in adolescents with Systemic Lupus Erythematosus"
120,"#25300","Yoon 2025","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"High","Observational - other",2025,"Eur J Cardiovasc Nurs",40085436,,"10.1093/eurjcn/zvaf033","https://pubmed.ncbi.nlm.nih.gov/40085436","Health-related quality of life in adolescents with myocarditis and pericarditis after BNT162b2 COVID-19 vaccination: Korean national surveillance"
120,"#25300","Yoon 2025","COVID",1,0,0,"Adult",0,0,1,1,0,0,"High","Observational - other",2025,"Eur J Cardiovasc Nurs",40085436,,"10.1093/eurjcn/zvaf033","https://pubmed.ncbi.nlm.nih.gov/40085436","Health-related quality of life in adolescents with myocarditis and pericarditis after BNT162b2 COVID-19 vaccination: Korean national surveillance"
121,"#38922","Jimeno Ruiz 2024","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"High","Cohort",2024,"Vaccines",39460326,"PMC11510999","10.3390/vaccines12101160","https://pmc.ncbi.nlm.nih.gov/articles/PMC11510999","Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain."
122,"#4622","Ann Costa Clemens 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2024,"Vaccine",38762360,"PMC11252665","10.1016/j.vaccine.2024.05.009","https://pmc.ncbi.nlm.nih.gov/articles/PMC11252665","Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice"
123,"#4716","Athan 2024","RSV",0,1,1,"Adult",0,0,0,0,1,0,"Low","RCT",2024,"Clin Infect Dis",37992000,"PMC11093669","10.1093/cid/ciad707","https://pmc.ncbi.nlm.nih.gov/articles/PMC11093669","Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults"
123,"#4716","Athan 2024","Influenza",0,1,1,"Adult",0,0,0,0,1,0,"Low","RCT",2024,"Clin Infect Dis",37992000,"PMC11093669","10.1093/cid/ciad707","https://pmc.ncbi.nlm.nih.gov/articles/PMC11093669","Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults"
124,"#4880","Baum 2024","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Low","RCT",2024,"Vaccine",38580516,,"10.1016/j.vaccine.2024.03.061","https://pubmed.ncbi.nlm.nih.gov/38580516","Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial"
124,"#4880","Baum 2024","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Low","RCT",2024,"Vaccine",38580516,,"10.1016/j.vaccine.2024.03.061","https://pubmed.ncbi.nlm.nih.gov/38580516","Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial"
125,"#416","Beller 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Vaccine",40561570,,"10.1016/j.vaccine.2025.127392","https://pubmed.ncbi.nlm.nih.gov/40561570","Impact of the medical briefing and vaccine type on adverse events following COVID-19 vaccination: A randomized clinical trial"
126,"#4933","Bennett 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Low","RCT",2024,"J Infect Dis",39052718,"PMC11272042","10.1093/infdis/jiad508","https://pmc.ncbi.nlm.nih.gov/articles/PMC11272042","Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial"
127,"#4932","Bennett 2024","COVID",1,0,0,"Immunocomp",0,0,0,1,0,1,"Low","RCT",2024,"J Infect",39343247,,"10.1016/j.jinf.2024.106285","https://pubmed.ncbi.nlm.nih.gov/39343247","Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial"
128,"#5191","Buynak 2024","RSV",0,1,0,"Adult",0,0,0,0,1,0,"Moderate","RCT",2024,"Infectious Diseases and Therapy",38981954,"PMC11266338","10.1007/s40121-024-00985-4","https://pmc.ncbi.nlm.nih.gov/articles/PMC11266338","Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged  65"
129,"#5332","Chalkias 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","RCT",2024,"J Infect Dis",38349280,"PMC11326827","10.1093/infdis/jiae067","https://pmc.ncbi.nlm.nih.gov/articles/PMC11326827","Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines"
130,"#13821","Chandler 2024","RSV",0,1,0,"Adult",0,0,0,0,1,0,"Moderate","RCT",2024,"Clin Infect Dis",38189778,,"10.1093/cid/ciad786","https://pubmed.ncbi.nlm.nih.gov/38189778","Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial"
131,"#763","Chime 2025","RSV",0,1,1,"Adult",0,0,0,1,0,0,"Moderate","RCT",2025,"J Infect Dis",38970327,"PMC11793055","10.1093/infdis/jiae342","https://pmc.ncbi.nlm.nih.gov/articles/PMC11793055","Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine"
131,"#763","Chime 2025","Influenza",0,1,1,"Adult",0,0,0,1,0,0,"Moderate","RCT",2025,"J Infect Dis",38970327,"PMC11793055","10.1093/infdis/jiae342","https://pmc.ncbi.nlm.nih.gov/articles/PMC11793055","Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine"
132,"#5532","Clark 2024","RSV",0,1,1,"Adult",0,0,0,0,1,0,"Moderate","RCT",2024,"Clin Infect Dis",39099085,"PMC11478588","10.1093/cid/ciae365","https://pmc.ncbi.nlm.nih.gov/articles/PMC11478588","Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial"
132,"#5532","Clark 2024","Influenza",0,1,1,"Adult",0,0,0,0,1,0,"Moderate","RCT",2024,"Clin Infect Dis",39099085,"PMC11478588","10.1093/cid/ciae365","https://pmc.ncbi.nlm.nih.gov/articles/PMC11478588","Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial"
134,"#907","Davis 2025","RSV",0,1,0,"Adult",0,0,0,1,0,0,"Low","RCT",2025,"Clin Infect Dis",39523547,"PMC12043053","10.1093/cid/ciae550","https://pmc.ncbi.nlm.nih.gov/articles/PMC12043053","Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions"
135,"#5965","Dulfer 2023","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Low","RCT",2023,"The Lancet Regional Health - Europe",37261212,"PMC10091277","10.1016/j.lanepe.2023.100628","https://pmc.ncbi.nlm.nih.gov/articles/PMC10091277","Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial"
135,"#5965","Dulfer 2023","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Low","RCT",2023,"The Lancet Regional Health - Europe",37261212,"PMC10091277","10.1016/j.lanepe.2023.100628","https://pmc.ncbi.nlm.nih.gov/articles/PMC10091277","Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial"
136,"#6180","Ferguson 2024","RSV",0,1,0,"Adult",0,0,0,1,1,0,"Moderate","RCT",2024,"Clin Infect Dis",39099093,"PMC11478578","10.1093/cid/ciae364","https://pmc.ncbi.nlm.nih.gov/articles/PMC11478578","Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to 60 Years of Age"
137,"#6376","Gao 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,0,0,"Low","RCT",2024,"Vaccine",39116486,,"10.1016/j.vaccine.2024.126182","https://pubmed.ncbi.nlm.nih.gov/39116486","Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial"
137,"#6376","Gao 2024","Influenza",0,0,1,"Adult",0,0,1,1,0,0,"Low","RCT",2024,"Vaccine",39116486,,"10.1016/j.vaccine.2024.126182","https://pubmed.ncbi.nlm.nih.gov/39116486","Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial"
138,"#6524","Goodyear 2024","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"High","RCT",2024,"Lancet Rheumatol",38734019,,"10.1016/s2665-9913(24)00065-1","https://pubmed.ncbi.nlm.nih.gov/38734019","Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial"
139,"#1388","Goswami 2025","COVID",1,1,1,"Adult",0,0,0,1,1,0,"Moderate","RCT",2025,"Lancet Infect Dis",39608389,,"10.1016/s1473-3099(24)00589-9","https://pubmed.ncbi.nlm.nih.gov/39608389","Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial"
139,"#1388","Goswami 2025","RSV",1,1,1,"Adult",0,0,0,1,1,0,"Moderate","RCT",2025,"Lancet Infect Dis",39608389,,"10.1016/s1473-3099(24)00589-9","https://pubmed.ncbi.nlm.nih.gov/39608389","Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial"
139,"#1388","Goswami 2025","Influenza",1,1,1,"Adult",0,0,0,1,1,0,"Moderate","RCT",2025,"Lancet Infect Dis",39608389,,"10.1016/s1473-3099(24)00589-9","https://pubmed.ncbi.nlm.nih.gov/39608389","Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial"
140,"#1665","Ison 2025","RSV",0,1,0,"Adult",0,0,0,1,1,0,"Moderate","RCT",2025,"Lancet Respir Med",40245915,,"10.1016/s2213-2600(25)00048-7","https://pubmed.ncbi.nlm.nih.gov/40245915","Efficacy, safety, and immunogenicity of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial"
142,"#1761","Jorda 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2025,"J Infect",39756693,,"10.1016/j.jinf.2024.106405","https://pubmed.ncbi.nlm.nih.gov/39756693","Immunogenicity, safety, and reactogenicity of concomitant administration of the novavax vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine in adults aged 60 years: A randomised, double-blind, placebo-controlled, non-inferiority trial"
144,"#7465","Khalid 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2024,"J Allergy Clin Immunol",38460680,"PMC11162316","10.1016/j.jaci.2024.03.001","https://pmc.ncbi.nlm.nih.gov/articles/PMC11162316","A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination"
145,"#2378","Marchese 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2025,"Vaccine",39643572,,"10.1016/j.vaccine.2024.126569","https://pubmed.ncbi.nlm.nih.gov/39643572","Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)"
147,"#8551","Meidani 2024","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"High","RCT",2024,"Russian Journal of Infection and Immunity",,,"10.15789/2220-7619-SAE-17550","https://doi.org/10.15789/2220-7619-SAE-17550","SAFETY AND EFFECTIVENESS OF SINGLE- VERSUS DOUBLE-DOSE OF SEASONAL INFLUENZA VACCINE IN KIDNEY TRANSPLANT RECIPIENTS: A RANDOMIZED CLINICAL TRIAL"
148,"#2581","MoreiraPuga 2025","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Low","RCT",2025,"The Lancet Regional Health - Americas",40083966,"PMC11904515","10.1016/j.lana.2025.101031","https://pmc.ncbi.nlm.nih.gov/articles/PMC11904515","Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil"
149,"#8828","Naficy 2024","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Moderate","RCT",2024,"Hum Vaccin Immunother",38513689,"PMC10962584","10.1080/21645515.2024.2327736","https://pmc.ncbi.nlm.nih.gov/articles/PMC10962584","No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial"
149,"#8828","Naficy 2024","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Moderate","RCT",2024,"Hum Vaccin Immunother",38513689,"PMC10962584","10.1080/21645515.2024.2327736","https://pmc.ncbi.nlm.nih.gov/articles/PMC10962584","No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial"
150,"#2779","Okada 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2025,"Lancet Infect Dis",39461355,,"10.1016/s1473-3099(24)00565-6","https://pubmed.ncbi.nlm.nih.gov/39461355","Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial"
151,"#9379","Prasert 2024","Influenza",0,0,1,"Adult",0,0,0,1,0,0,"Low","RCT",2024,"Vaccine",38042698,"PMC10733862","10.1016/j.vaccine.2023.11.050","https://pmc.ncbi.nlm.nih.gov/articles/PMC10733862","Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial"
152,"#9507","Ramsay 2023","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Low","RCT",2023,"Vaccine",37903680,,"10.1016/j.vaccine.2023.10.050","https://pubmed.ncbi.nlm.nih.gov/37903680","A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)"
152,"#9507","Ramsay 2023","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Low","RCT",2023,"Vaccine",37903680,,"10.1016/j.vaccine.2023.10.050","https://pubmed.ncbi.nlm.nih.gov/37903680","A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)"
154,"#9910","Schmader 2024","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","RCT",2024,"JAMA Netw Open",39446325,"PMC11581605","10.1001/jamanetworkopen.2024.40817","https://pmc.ncbi.nlm.nih.gov/articles/PMC11581605","Safety of Simultaneous Vaccination With Adjuvanted Zoster Vaccine and Adjuvanted Influenza Vaccine: A Randomized Clinical Trial"
159,"#10879","Walter 2024","COVID",1,0,1,"Pediatric",0,0,1,1,1,0,"Low","RCT",2024,"JAMA Netw Open",39504023,"PMC11541642","10.1001/jamanetworkopen.2024.43166","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541642","Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial"
159,"#10879","Walter 2024","Influenza",1,0,1,"Pediatric",0,0,1,1,1,0,"Low","RCT",2024,"JAMA Netw Open",39504023,"PMC11541642","10.1001/jamanetworkopen.2024.43166","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541642","Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial"
159,"#10879","Walter 2024","COVID",1,0,1,"Adult",0,0,1,1,1,0,"Low","RCT",2024,"JAMA Netw Open",39504023,"PMC11541642","10.1001/jamanetworkopen.2024.43166","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541642","Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial"
159,"#10879","Walter 2024","Influenza",1,0,1,"Adult",0,0,1,1,1,0,"Low","RCT",2024,"JAMA Netw Open",39504023,"PMC11541642","10.1001/jamanetworkopen.2024.43166","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541642","Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial"
161,"#8982","Ocek 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Noropsikiyatri Arsivi",39258123,"PMC11382557","10.29399/npa.28418","https://pmc.ncbi.nlm.nih.gov/articles/PMC11382557","Evaluation of Clinical Effects of COVID-19 Infection and Vaccines on Myasthenia Gravis"
162,"#9094","Ozdemir 2024","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"High","Observational - other",2024,"Alergologia Polska - Polish Journal of Allergology",,,"10.5114/pja.2024.138498","https://doi.org/10.5114/pja.2024.138498","The effect of COVID-19 and COVID-19 vaccines on chronic spontaneous urticaria: single center experience"
162,"#9094","Ozdemir 2024","COVID",1,0,0,"Adult",0,0,1,1,0,0,"High","Observational - other",2024,"Alergologia Polska - Polish Journal of Allergology",,,"10.5114/pja.2024.138498","https://doi.org/10.5114/pja.2024.138498","The effect of COVID-19 and COVID-19 vaccines on chronic spontaneous urticaria: single center experience"
163,"#4695","Turan 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Acta Neurol Belg",38619748,,"10.1007/s13760-024-02536-7","https://pubmed.ncbi.nlm.nih.gov/38619748","A retrospective cohort study: is COVID-19 BNT162b2 mRNA vaccination a trigger factor for cluster headache?"
164,"#19","Abdul Rahim 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2025,"BMC Public Health",40055620,"PMC11889865","10.1186/s12889-025-21765-w","https://pmc.ncbi.nlm.nih.gov/articles/PMC11889865","Association of COVID-19 infection and COVID-19 vaccination with idiopathic sudden sensorineural hearing loss in Malaysia: a case-control study"
165,"#4320","Abdurakhmanov 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Moderate","Observational - other",2024,"VacciMonitor",,,,"https://scielo.sld.cu/pdf/vac/v33/1025-0298-vac-33-e073324.pdf","Effect of inactivated and mRNA COVID-19 vaccines on thrombocytopenia in immune thrombocytopenia patients"
166,"#24","Abou Chakra 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2025,"Emerg Microbes Infect",40071892,"PMC11980197","10.1080/22221751.2025.2466699","https://pmc.ncbi.nlm.nih.gov/articles/PMC11980197","Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024"
166,"#24","Abou Chakra 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2025,"Emerg Microbes Infect",40071892,"PMC11980197","10.1080/22221751.2025.2466699","https://pmc.ncbi.nlm.nih.gov/articles/PMC11980197","Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024"
167,"#4303","Ab Rahman 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Observational - other",2024,"Vaccine",39447251,,"10.1016/j.vaccine.2024.126465","https://pubmed.ncbi.nlm.nih.gov/39447251","Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study"
168,"#4340","Abukhalil 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"International Journal of General Medicine",39100722,"PMC11297544","10.2147/IJGM.S466838","https://pmc.ncbi.nlm.nih.gov/articles/PMC11297544","COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine"
168,"#4340","Abukhalil 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"International Journal of General Medicine",39100722,"PMC11297544","10.2147/IJGM.S466838","https://pmc.ncbi.nlm.nih.gov/articles/PMC11297544","COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine"
170,"#40","Acuti Martellucci 2025","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Vaccines",40266236,"PMC11946095","10.3390/vaccines13030309","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946095","The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study"
171,"#46","Adelglass 2025","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2025,"J Allergy Clin Immunol",40154575,,"10.1016/j.jaci.2025.03.015","https://pubmed.ncbi.nlm.nih.gov/40154575","Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses"
172,"#4362","Adin 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Nucl Med Commun",38465449,,"10.1097/mnm.0000000000001833","https://pubmed.ncbi.nlm.nih.gov/38465449","Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines"
173,"#4368","Aftab 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Ophthalmology",38242364,,"10.1016/j.ophtha.2024.01.020","https://pubmed.ncbi.nlm.nih.gov/38242364","Ophthalmologic Complications in Coronavirus Disease 2019 Immunization: A National Vaccine Adverse Event Reporting System Analysis"
173,"#4368","Aftab 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Ophthalmology",38242364,,"10.1016/j.ophtha.2024.01.020","https://pubmed.ncbi.nlm.nih.gov/38242364","Ophthalmologic Complications in Coronavirus Disease 2019 Immunization: A National Vaccine Adverse Event Reporting System Analysis"
174,"#77","Ahmed Al Qahtani 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Clinical Epidemiology and Global Health",,,"10.1016/j.cegh.2025.101975","https://doi.org/10.1016/j.cegh.2025.101975","Short and long-term side effects of eligible COVID-19 vaccines in Saudi Arabia, Southern Region, 2023"
176,"#4459","Al-Rousan 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Informatics in Medicine Unlocked",,,"10.1016/j.imu.2024.101564","https://doi.org/10.1016/j.imu.2024.101564","Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis"
176,"#4459","Al-Rousan 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Informatics in Medicine Unlocked",,,"10.1016/j.imu.2024.101564","https://doi.org/10.1016/j.imu.2024.101564","Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis"
177,"#4476","Alawfi 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"International Journal of Women's Health",39421715,"PMC11484768","10.2147/IJWH.S472953","https://pmc.ncbi.nlm.nih.gov/articles/PMC11484768","Health of Saudi Women in the Post-Pandemic Era: Candidiasis Incidence and Post COVID-19 and COVID-19-Vaccination"
178,"#119","Albahari 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Exploratory Research in Clinical and Social Pharmacy",40502459,"PMC12152863","10.1016/j.rcsop.2025.100614","https://pmc.ncbi.nlm.nih.gov/articles/PMC12152863","Impact of mRNA COVID-19 vaccination on hematological parameters in patients maintained on clozapine: A retrospective study from Qatar"
180,"#13033","Ali 2024","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"High","Observational - other",2024,"Heart Views",40488147,"PMC12139649","10.4103/heartviews.heartviews_62_24","https://pmc.ncbi.nlm.nih.gov/articles/PMC12139649","A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination"
180,"#13033","Ali 2024","COVID",1,0,0,"Adult",0,0,1,1,0,0,"High","Observational - other",2024,"Heart Views",40488147,"PMC12139649","10.4103/heartviews.heartviews_62_24","https://pmc.ncbi.nlm.nih.gov/articles/PMC12139649","A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination"
182,"#156","Almeida 2025","RSV",0,1,0,"Immunocomp",0,0,0,1,1,1,"High","Observational - other",2025,"Vaccines",40266222,"PMC11946143","10.3390/vaccines13030328","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946143","Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults"
183,"#4532","Almodovar-Fernandez 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Vacunas",,,"10.1016/j.vacun.2024.04.004","https://doi.org/10.1016/j.vacun.2024.04.004","SARS-CoV-2 vaccination effect over coagulation in 60s patients treated with acenocumarol"
185,"#178","Alves 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Vaccine",40184816,,"10.1016/j.vaccine.2025.127046","https://pubmed.ncbi.nlm.nih.gov/40184816","Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study"
186,"#183","Amaral de Avila Machado 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Hum Vaccin Immunother",40098448,,"10.1080/21645515.2025.2475616","https://pubmed.ncbi.nlm.nih.gov/40098448","Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season"
186,"#183","Amaral de Avila Machado 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Hum Vaccin Immunother",40098448,,"10.1080/21645515.2025.2475616","https://pubmed.ncbi.nlm.nih.gov/40098448","Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season"
187,"#4579","Amicizia 2023","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"High","Observational - other",2023,"Hum Vaccin Immunother",36919537,"PMC10072113","10.1080/21645515.2023.2190279","https://pmc.ncbi.nlm.nih.gov/articles/PMC10072113","Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season"
188,"#4590","Amstutz 2024","COVID",1,0,0,"Immunocomp",0,0,1,1,1,1,"High","Observational - other",2024,"J Infect Dis",38848312,"PMC11481330","10.1093/infdis/jiae291","https://pmc.ncbi.nlm.nih.gov/articles/PMC11481330","Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study"
189,"#202","Andersen 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Vaccine",39987879,,"10.1016/j.vaccine.2025.126881","https://pubmed.ncbi.nlm.nih.gov/39987879","Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states"
190,"#13126","Andersson 2024","COVID",1,0,0,"Adult",0,0,0,0,1,0,"Low","Cohort",2024,"BMJ Med",39902239,"PMC11789462","10.1136/bmjmed-2024-001074","https://pmc.ncbi.nlm.nih.gov/articles/PMC11789462","Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data"
194,"#233","Appaneal 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2025,"Nat Commun",40301395,"PMC12041242","10.1038/s41467-025-59344-7","https://pmc.ncbi.nlm.nih.gov/articles/PMC12041242","Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System"
195,"#20412","Arcolaci 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Vaccine",40479930,,"10.1016/j.vaccine.2025.127337","https://pubmed.ncbi.nlm.nih.gov/40479930","A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines"
196,"#244","Arepalli 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Retina",39841907,,"10.1097/iae.0000000000004413","https://pubmed.ncbi.nlm.nih.gov/39841907","THE HETEROGENEOUS PRESENTATIONS OF DE NOVO AND RECURRENT OCULAR INFLAMMATION AFTER COVID-19 VACCINATION : A Multicenter Report and a Review of the Literature"
197,"#20449","Asiri 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Int J Gen Med",40547349,,"10.2147/ijgm.S520084","https://pubmed.ncbi.nlm.nih.gov/40547349","Adverse Cutaneous Reactions Following COVID-19 Vaccination Among Patients with Pre-Existing Urticaria: A Cross-Sectional Study at a Tertiary Care Center in Saudi Arabia"
199,"#4742","Aydillo 2024","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Moderate","Cohort",2024,"Emerg Microbes Infect",38054302,"PMC10798284","10.1080/22221751.2023.2292068","https://pmc.ncbi.nlm.nih.gov/articles/PMC10798284","Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines"
199,"#4742","Aydillo 2024","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Moderate","Cohort",2024,"Emerg Microbes Infect",38054302,"PMC10798284","10.1080/22221751.2023.2292068","https://pmc.ncbi.nlm.nih.gov/articles/PMC10798284","Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines"
200,"#4744","Aydin 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Journal of Experimental and Clinical Medicine (Turkey)",,,"10.52142/omujecm.41.2.13","https://doi.org/10.52142/omujecm.41.2.13","Effect of COVID-19 mRNA vaccine on serum AMH, TSH, FSH and LH concentrations"
201,"#4765","Baba 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"J Dermatol",38605482,,"10.1111/1346-8138.17188","https://pubmed.ncbi.nlm.nih.gov/38605482","Cutaneous adverse events following COVID-19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies"
201,"#4765","Baba 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"J Dermatol",38605482,,"10.1111/1346-8138.17188","https://pubmed.ncbi.nlm.nih.gov/38605482","Cutaneous adverse events following COVID-19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies"
202,"#314","Babalola 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2025,"The Lancet Regional Health - Americas",39866362,"PMC11764319","10.1016/j.lana.2024.100984","https://pmc.ncbi.nlm.nih.gov/articles/PMC11764319","SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study"
203,"#4774","Baden 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2024,"Nat Commun",39209823,"PMC11362294","10.1038/s41467-024-50376-z","https://pmc.ncbi.nlm.nih.gov/articles/PMC11362294","Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases"
204,"#328","Bahakel 2025","Influenza",0,0,1,"Immunocomp",0,0,1,0,0,1,"High","Observational - other",2025,"J Infect Dis",39279435,"PMC11793066","10.1093/infdis/jiae454","https://pmc.ncbi.nlm.nih.gov/articles/PMC11793066","Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season"
205,"#338","Bajema 2025","RSV",0,1,0,"Immunocomp",0,0,0,0,1,1,"Low","Cohort",2025,"LANCET INFECTIOUS DISEASES",39848264,,"10.1016/S1473-3099(24)00796-5","https://pubmed.ncbi.nlm.nih.gov/39848264","Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study"
206,"#337","Bajema 2025","COVID",1,1,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"JAMA Intern Med",39869355,"PMC11773409","10.1001/jamainternmed.2024.7452","https://pmc.ncbi.nlm.nih.gov/articles/PMC11773409","Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus"
206,"#337","Bajema 2025","RSV",1,1,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"JAMA Intern Med",39869355,"PMC11773409","10.1001/jamainternmed.2024.7452","https://pmc.ncbi.nlm.nih.gov/articles/PMC11773409","Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus"
206,"#337","Bajema 2025","Influenza",1,1,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"JAMA Intern Med",39869355,"PMC11773409","10.1001/jamainternmed.2024.7452","https://pmc.ncbi.nlm.nih.gov/articles/PMC11773409","Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus"
207,"#367","Barnay 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2025,"Rev Neurol (Paris)",40307085,,"10.1016/j.neurol.2025.04.007","https://pubmed.ncbi.nlm.nih.gov/40307085","The safety of COVID-19 vaccines in a large French series of patients with neuromuscular conditions and the impacts of vaccination on their daily lives"
208,"#4849","Barouch 2024","COVID",1,0,1,"Adult",0,0,0,1,1,0,"High","Cohort",2024,"Open Forum Infectious Diseases",38567194,"PMC10986856","10.1093/ofid/ofae144","https://pmc.ncbi.nlm.nih.gov/articles/PMC10986856","Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses"
208,"#4849","Barouch 2024","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"High","Cohort",2024,"Open Forum Infectious Diseases",38567194,"PMC10986856","10.1093/ofid/ofae144","https://pmc.ncbi.nlm.nih.gov/articles/PMC10986856","Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses"
209,"#4877","Battis 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Dermatitis",38535725,,"10.1089/derm.2023.0379","https://pubmed.ncbi.nlm.nih.gov/38535725","Patient-Reported Association Between COVID-19 Infection or Vaccination and Onset of Allergic Contact Dermatitis"
210,"#4916","Bellitto 2024","COVID",1,0,0,"Immunocomp",0,0,0,0,0,1,"High","Cohort",2024,"Drug Saf",38907947,"PMC11399172","10.1007/s40264-024-01449-x","https://pmc.ncbi.nlm.nih.gov/articles/PMC11399172","What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European ""Covid Vaccine Monitor"" Active Surveillance Study"
211,"#13419","Ben Kridis 2024","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"High","Observational - other",2024,"J Oncol Pharm Pract",39285730,,"10.1177/10781552241285034","https://pubmed.ncbi.nlm.nih.gov/39285730","Local and systemic side effects of COVID-19 vaccine in Tunisian cancer patients: A prospective single center study"
212,"#448","Beurrier 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Therapie",39294069,,"10.1016/j.therap.2024.08.002","https://pubmed.ncbi.nlm.nih.gov/39294069","Retinal vascular occlusion after COVID-19 vaccination: Analysis of the French pharmacovigilance database"
212,"#448","Beurrier 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Therapie",39294069,,"10.1016/j.therap.2024.08.002","https://pubmed.ncbi.nlm.nih.gov/39294069","Retinal vascular occlusion after COVID-19 vaccination: Analysis of the French pharmacovigilance database"
213,"#4993","Biegus 2024","RSV",0,1,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Vaccine",38531725,,"10.1016/j.vaccine.2024.03.060","https://pubmed.ncbi.nlm.nih.gov/38531725","The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure"
213,"#4993","Biegus 2024","Influenza",0,1,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Vaccine",38531725,,"10.1016/j.vaccine.2024.03.060","https://pubmed.ncbi.nlm.nih.gov/38531725","The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure"
216,"#484","Blanquart 2025","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Case-control",2025,"Euro Surveill",39980426,,"10.2807/1560-7917.Es.2025.30.7.2500074","https://pubmed.ncbi.nlm.nih.gov/39980426","Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025"
218,"#506","Bolu 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Vaccine",40073670,"PMC11975468","10.1016/j.vaccine.2025.126907","https://pmc.ncbi.nlm.nih.gov/articles/PMC11975468","Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021"
220,"#5079","Bosch 2024","RSV",0,1,0,"Adult",0,0,0,1,0,0,"Low","Cohort",2024,"Open Forum Infectious Diseases",39474445,"PMC11521338","10.1093/ofid/ofae597","https://pmc.ncbi.nlm.nih.gov/articles/PMC11521338","Incidence of Respiratory Syncytial Virus in Community-Dwelling Adults Aged 18-64 Years Over 2 Seasons, 2022-2024, in a North American Community"
222,"#525","Boulefaa 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Drug Saf",39638989,"PMC11829932","10.1007/s40264-024-01495-5","https://pmc.ncbi.nlm.nih.gov/articles/PMC11829932","Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database"
225,"#548","Briggs 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Mult Scler Relat Disord",39756168,,"10.1016/j.msard.2024.106253","https://pubmed.ncbi.nlm.nih.gov/39756168","Self-reported longitudinal COVID-19 vaccination reactogenicity profiles in persons with multiple sclerosis"
226,"#5193","Byoun 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Sci Rep",39420039,"PMC11487014","10.1038/s41598-024-73940-5","https://pmc.ncbi.nlm.nih.gov/articles/PMC11487014","Nationwide Cohort observational study on the safety and efficacy of COVID-19 vaccination in patients with Moyamoya disease"
227,"#5200","Caffrey 2024","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"Low","Case-control",2024,"Nat Commun",39488521,"PMC11531596","10.1038/s41467-024-53842-w","https://pmc.ncbi.nlm.nih.gov/articles/PMC11531596","Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System"
228,"#630","Carazo 2025","COVID",1,0,0,"Adult",0,0,0,0,1,0,"High","Case-control",2025,"PLoS One",40460407,"PMC12133164","10.1371/journal.pone.0325269","https://pmc.ncbi.nlm.nih.gov/articles/PMC12133164","Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up"
235,"#5392","Chemaitelly 2024","COVID",1,0,0,"Pediatric",0,1,1,1,1,0,"Low","Case-control",2024,"Int J Infect Dis",38777080,,"10.1016/j.ijid.2024.107095","https://pubmed.ncbi.nlm.nih.gov/38777080","Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar"
235,"#5392","Chemaitelly 2024","COVID",1,0,0,"Adult",0,1,1,1,1,0,"Low","Case-control",2024,"Int J Infect Dis",38777080,,"10.1016/j.ijid.2024.107095","https://pubmed.ncbi.nlm.nih.gov/38777080","Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar"
236,"#5393","Chemaitelly 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Influenza Other Respir Viruses",39343986,"PMC11439586","10.1111/irv.13357","https://pmc.ncbi.nlm.nih.gov/articles/PMC11439586","BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar"
236,"#5393","Chemaitelly 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Influenza Other Respir Viruses",39343986,"PMC11439586","10.1111/irv.13357","https://pmc.ncbi.nlm.nih.gov/articles/PMC11439586","BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar"
238,"#5400","Chen 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Journal of Clinical Medicine",39124761,"PMC11313347","10.3390/jcm13154494","https://pmc.ncbi.nlm.nih.gov/articles/PMC11313347","De Novo Biopsy-Proven Glomerular Disease Following COVID-19 Vaccination"
239,"#5402","Chen 2024","COVID",1,0,0,"Immunocomp",0,0,1,1,1,1,"Low","Observational - other",2024,"BMC Med",38858672,"PMC11165729","10.1186/s12916-024-03457-1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11165729","Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England"
240,"#706","Chen 2025","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"Low","Observational - other",2025,"eClinicalMedicine",40276143,"PMC12018050","10.1016/j.eclinm.2025.103171","https://pmc.ncbi.nlm.nih.gov/articles/PMC12018050","Interaction between influenza vaccine and statins affecting the risk of rhabdomyolysis in Taiwan: a nationwide case-centred analysis"
241,"#5454","Cheng 2024","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"Low","Observational - other",2024,"Vaccine",38897892,,"10.1016/j.vaccine.2024.06.042","https://pubmed.ncbi.nlm.nih.gov/38897892","Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine"
243,"#20993","Cheng 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2025,"J Clin Endocrinol Metab",39883558,,"10.1210/clinem/dgaf064","https://pubmed.ncbi.nlm.nih.gov/39883558","Long-term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2,333,496 Patients from the TriNetX Network"
243,"#20993","Cheng 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2025,"J Clin Endocrinol Metab",39883558,,"10.1210/clinem/dgaf064","https://pubmed.ncbi.nlm.nih.gov/39883558","Long-term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2,333,496 Patients from the TriNetX Network"
244,"#5464","Chewaskulyong 2024","COVID",1,0,0,"Immunocomp",0,0,0,0,0,1,"High","Observational - other",2024,"PLoS One",39509358,"PMC11542819","10.1371/journal.pone.0310781","https://pmc.ncbi.nlm.nih.gov/articles/PMC11542819","Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients"
245,"#5478","Cho 2024","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Observational - other",2024,"Pharmacoepidemiol Drug Saf",39238434,,"10.1002/pds.70006","https://pubmed.ncbi.nlm.nih.gov/39238434","Association Between Influenza Vaccination and Acute Kidney Injury Among the Elderly: A Self-Controlled Case Series"
246,"#768","Cho 2025","Influenza",0,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2025,"J Korean Med Sci",40132537,"PMC11932827","10.3346/jkms.2025.40.e101","https://pmc.ncbi.nlm.nih.gov/articles/PMC11932827","Global Burden of Vaccine-Associated Cerebrovascular Venous Sinus Thrombosis, 1968-2024: A Critical Analysis From the WHO Global Pharmacovigilance Database"
246,"#768","Cho 2025","Influenza",0,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2025,"J Korean Med Sci",40132537,"PMC11932827","10.3346/jkms.2025.40.e101","https://pmc.ncbi.nlm.nih.gov/articles/PMC11932827","Global Burden of Vaccine-Associated Cerebrovascular Venous Sinus Thrombosis, 1968-2024: A Critical Analysis From the WHO Global Pharmacovigilance Database"
247,"#5483","Choi 2024","COVID",1,0,1,"Adult",0,0,0,1,1,0,"High","RCT",2024,"Clin Microbiol Infect",38253313,,"10.1016/j.cmi.2024.01.010","https://pubmed.ncbi.nlm.nih.gov/38253313","Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference"
247,"#5483","Choi 2024","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"High","RCT",2024,"Clin Microbiol Infect",38253313,,"10.1016/j.cmi.2024.01.010","https://pubmed.ncbi.nlm.nih.gov/38253313","Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference"
248,"#5489","Choi 2024","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"High","Case-control",2024,"J Korean Med Sci",38651226,"PMC11035711","10.3346/jkms.2024.39.e146","https://pmc.ncbi.nlm.nih.gov/articles/PMC11035711","Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea"
250,"#784","Choi 2025","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"Moderate","Case-control",2025,"Vaccines",40006743,"PMC11861641","10.3390/vaccines13020197","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861641","Early and Late Influenza Vaccine Effectiveness in South Korea During the 20232024 Season"
251,"#776","Choi 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Open Forum Infectious Diseases",40110421,"PMC11919815","10.1093/ofid/ofaf115","https://pmc.ncbi.nlm.nih.gov/articles/PMC11919815","Rates of Hospitalization and Death due to COVID-19 in US Veterans with SARS-CoV-2 Infection in the XBB-, JN.1-, and KP-Predominant Eras"
252,"#5494","Chong 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Clin Infect Dis",38922669,,"10.1093/cid/ciae339","https://pubmed.ncbi.nlm.nih.gov/38922669","Risks of SARS-CoV-2 JN.1 Infection and COVID-19-Associated Emergency Department Visits/Hospitalizations Following Updated Boosters and Prior Infection: A Population-Based Cohort Study"
253,"#21056","Chung 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2025,"Clin Infect Dis",39761230,"PMC12287938","10.1093/cid/ciae658","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287938","Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season"
253,"#21056","Chung 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2025,"Clin Infect Dis",39761230,"PMC12287938","10.1093/cid/ciae658","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287938","Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season"
254,"#5539","Clothier 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Euro Surveill",39668765,,"10.2807/1560-7917.Es.2024.29.50.2400164","https://pubmed.ncbi.nlm.nih.gov/39668765","Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023"
254,"#5539","Clothier 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Euro Surveill",39668765,,"10.2807/1560-7917.Es.2024.29.50.2400164","https://pubmed.ncbi.nlm.nih.gov/39668765","Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023"
255,"#5595","Costantino 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2024,"Vaccines",38543939,"PMC10976042","10.3390/vaccines12030305","https://pmc.ncbi.nlm.nih.gov/articles/PMC10976042","Mid-Term Estimates of Influenza Vaccine Effectiveness against the A(H1N1)pdm09 Prevalent Circulating Subtype in the 2023/24 Season: Data from the Sicilian RespiVirNet Surveillance System"
255,"#5595","Costantino 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2024,"Vaccines",38543939,"PMC10976042","10.3390/vaccines12030305","https://pmc.ncbi.nlm.nih.gov/articles/PMC10976042","Mid-Term Estimates of Influenza Vaccine Effectiveness against the A(H1N1)pdm09 Prevalent Circulating Subtype in the 2023/24 Season: Data from the Sicilian RespiVirNet Surveillance System"
256,"#5609","Couvillion 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"J Nutr",39396761,"PMC11662230","10.1016/j.tjnut.2024.09.032","https://pmc.ncbi.nlm.nih.gov/articles/PMC11662230","Associations between SARS-CoV-2 Infection or COVID-19 Vaccination and Human Milk Composition: A Multi-Omics Approach"
259,"#5696","Darko 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Cohort",2024,"Vaccine",39447252,,"10.1016/j.vaccine.2024.126460","https://pubmed.ncbi.nlm.nih.gov/39447252","Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study"
259,"#5696","Darko 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Cohort",2024,"Vaccine",39447252,,"10.1016/j.vaccine.2024.126460","https://pubmed.ncbi.nlm.nih.gov/39447252","Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study"
260,"#871","da Silva 2025","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"High","Observational - other",2025,"Gastroenterol Hepatol",38723765,,"10.1016/j.gastrohep.2024.502202","https://pubmed.ncbi.nlm.nih.gov/38723765","Vaccine adherence and adverse events of the SARS-COV vaccine in patients with inflammatory bowel disease"
261,"#5779","de-la-Plaza-San-Frutos 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Frontiers in Medicine",38983365,"PMC11231098","10.3389/fmed.2024.1338317","https://pmc.ncbi.nlm.nih.gov/articles/PMC11231098","Effects of vaccination against COVID-19 on overactive bladder symptoms on young population"
262,"#5758","de la Cueva 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Drug Saf",38949714,"PMC11485106","10.1007/s40264-024-01456-y","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485106","Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season"
262,"#5758","de la Cueva 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Drug Saf",38949714,"PMC11485106","10.1007/s40264-024-01456-y","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485106","Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season"
263,"#5811","Deshmukh 2024","COVID",1,0,0,"Adult",0,0,0,0,1,0,"Low","Cohort",2024,"J Cardiovasc Electrophysiol",39039649,,"10.1111/jce.16372","https://pubmed.ncbi.nlm.nih.gov/39039649","Association between COVID-19 vaccination and atrial arrhythmias in individuals with cardiac implantable electronic devices"
264,"#1001","Diya 2025","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2025,"Vaccine",39999538,,"10.1016/j.vaccine.2025.126869","https://pubmed.ncbi.nlm.nih.gov/39999538","A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults 18 years old"
265,"#5888","Domnich 2024","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"Low","Case-control",2024,"Int J Infect Dis",39122207,,"10.1016/j.ijid.2024.107202","https://pubmed.ncbi.nlm.nih.gov/39122207","Influenza epidemiology and vaccine effectiveness during the 2023/2024 season in Italy: A test-negative case-control study"
266,"#1013","Domnich 2025","RSV",0,1,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"VACCINE: X",,,"10.1016/j.jvacx.2025.100647","https://doi.org/10.1016/j.jvacx.2025.100647","Enhanced safety surveillance of the adjuvanted respiratory syncytial virus vaccine among Italian older adults"
269,"#5917","Dos Santos 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Drug Saf",38483767,"PMC10955014","10.1007/s40264-024-01395-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC10955014","An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older"
269,"#5917","Dos Santos 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Drug Saf",38483767,"PMC10955014","10.1007/s40264-024-01395-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC10955014","An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older"
271,"#1051","Dudukina 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Moderate","Cohort",2025,"Scand J Public Health",40439194,,"10.1177/14034948251333901","https://pubmed.ncbi.nlm.nih.gov/40439194","Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark"
271,"#1051","Dudukina 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Moderate","Cohort",2025,"Scand J Public Health",40439194,,"10.1177/14034948251333901","https://pubmed.ncbi.nlm.nih.gov/40439194","Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark"
272,"#5982","Duskin-Bitan 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2024,"Endocr Pract",38729568,,"10.1016/j.eprac.2024.05.001","https://pubmed.ncbi.nlm.nih.gov/38729568","Subacute Thyroiditis Following COVID-19 and COVID-19 Vaccination"
274,"#6041","Elbaz 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2024,"Open Forum Infectious Diseases",38868305,"PMC11167675","10.1093/ofid/ofae287","https://pmc.ncbi.nlm.nih.gov/articles/PMC11167675","Varicella-Zoster Virus-Induced Neurologic Disease After COVID-19 Vaccination: A Multicenter Observational Cohort Study"
275,"#6043","Elemuwa 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Journal of Population Therapeutics and Clinical Pharmacology",,,"10.53555/6vk1cf91","https://doi.org/10.53555/6vk1cf91","TRENDS OF COVID-19 VACCINE ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI): A ONE-YEAR RETROSPECTIVE REVIEW USING THE PASSIVE SURVEILLANCE DATA IN THE NIGERIAN NATIONAL DATABASE (VIGIFLOW)"
275,"#6043","Elemuwa 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Journal of Population Therapeutics and Clinical Pharmacology",,,"10.53555/6vk1cf91","https://doi.org/10.53555/6vk1cf91","TRENDS OF COVID-19 VACCINE ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI): A ONE-YEAR RETROSPECTIVE REVIEW USING THE PASSIVE SURVEILLANCE DATA IN THE NIGERIAN NATIONAL DATABASE (VIGIFLOW)"
276,"#1107","Emborg 2025","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Case-control",2025,"Euro Surveill",40156348,,"10.2807/1560-7917.Es.2025.30.12.2500174","https://pubmed.ncbi.nlm.nih.gov/40156348","Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025"
278,"#1117","Erdwiens 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2025,"Influenza Other Respir Viruses",40328669,"PMC12055342","10.1111/irv.70115","https://pmc.ncbi.nlm.nih.gov/articles/PMC12055342","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance"
278,"#1117","Erdwiens 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2025,"Influenza Other Respir Viruses",40328669,"PMC12055342","10.1111/irv.70115","https://pmc.ncbi.nlm.nih.gov/articles/PMC12055342","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance"
279,"#6099","Esteban-Cledera 2024","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"Low","Cohort",2024,"Int J Environ Res Public Health",39200699,"PMC11354165","10.3390/ijerph21081090","https://pmc.ncbi.nlm.nih.gov/articles/PMC11354165","Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain"
279,"#6099","Esteban-Cledera 2024","COVID",1,0,0,"Adult",0,0,1,1,0,0,"Low","Cohort",2024,"Int J Environ Res Public Health",39200699,"PMC11354165","10.3390/ijerph21081090","https://pmc.ncbi.nlm.nih.gov/articles/PMC11354165","Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain"
280,"#21482","Fabbri 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Cancers (Basel)",40563598,"PMC12191419","10.3390/cancers17121948","https://pmc.ncbi.nlm.nih.gov/articles/PMC12191419","Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study"
281,"#6143","Farisogullari 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2024,"Ann Rheum Dis",38816065,"PMC11503143","10.1136/ard-2024-225869","https://pmc.ncbi.nlm.nih.gov/articles/PMC11503143","Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry"
282,"#1175","Fatima 2025","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2025,"Journal of Population Therapeutics and Clinical Pharmacology",,,"10.53555/thn9g804","https://doi.org/10.53555/thn9g804","MENSTRUAL IRREGULARITIES IN WOMEN AFTER COVID-19 INFECTION AND VACCINATION: A COMMUNITY BASED STUDY AMONG DUBAI HOSPITAL FEMALE STAFF AND WOMEN ATTENDING GYNECOLOGY CLINIC AND EMERGENCY"
283,"#1199","Ferraioli 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Vaccines",40333295,"PMC12031101","10.3390/vaccines13040396","https://pmc.ncbi.nlm.nih.gov/articles/PMC12031101","Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies"
284,"#6193","Ferrari 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Intern Emerg Med",39042210,,"10.1007/s11739-024-03641-4","https://pubmed.ncbi.nlm.nih.gov/39042210","Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting"
284,"#6193","Ferrari 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Intern Emerg Med",39042210,,"10.1007/s11739-024-03641-4","https://pubmed.ncbi.nlm.nih.gov/39042210","Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting"
286,"#1208","Fierro 2025","COVID",1,1,0,"Adult",0,0,0,1,1,0,"Low","RCT",2025,"Front Immunol",40276503,"PMC12018429","10.3389/fimmu.2025.1501275","https://pmc.ncbi.nlm.nih.gov/articles/PMC12018429","Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study"
286,"#1208","Fierro 2025","RSV",1,1,0,"Adult",0,0,0,1,1,0,"Low","RCT",2025,"Front Immunol",40276503,"PMC12018429","10.3389/fimmu.2025.1501275","https://pmc.ncbi.nlm.nih.gov/articles/PMC12018429","Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study"
287,"#6209","Figueroa 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"J Infect Dis",38513368,"PMC11420796","10.1093/infdis/jiae140","https://pmc.ncbi.nlm.nih.gov/articles/PMC11420796","Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients"
288,"#1221","Fitzpatrick 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Vaccine",40398329,,"10.1016/j.vaccine.2025.127254","https://pubmed.ncbi.nlm.nih.gov/40398329","Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network"
288,"#1221","Fitzpatrick 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Vaccine",40398329,,"10.1016/j.vaccine.2025.127254","https://pubmed.ncbi.nlm.nih.gov/40398329","Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network"
290,"#6252","Fonseca 2024","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"Low","RCT",2024,"Vaccine",38154990,,"10.1016/j.vaccine.2023.12.074","https://pubmed.ncbi.nlm.nih.gov/38154990","In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial"
291,"#6253","Fontana 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Am J Gastroenterol",38314748,"PMC11296936","10.14309/ajg.0000000000002702","https://pmc.ncbi.nlm.nih.gov/articles/PMC11296936","ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study"
292,"#6266","Fotakis 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Vaccine",39298999,,"10.1016/j.vaccine.2024.126375","https://pubmed.ncbi.nlm.nih.gov/39298999","Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024)"
293,"#1246","Fraenza 2025","COVID",1,0,0,"Immunocomp",0,1,1,1,1,1,"High","Observational - other",2025,"Sci Rep",40289148,"PMC12034749","10.1038/s41598-025-98313-4","https://pmc.ncbi.nlm.nih.gov/articles/PMC12034749","Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination"
294,"#21621","Frankenthal 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"PLoS One",40644466,"PMC12250466","10.1371/journal.pone.0326231","https://pmc.ncbi.nlm.nih.gov/articles/PMC12250466","Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients"
295,"#6300","Frutos 2024","Influenza",0,0,1,"Pediatric",0,0,1,0,1,0,"Low","Case-control",2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
295,"#6300","Frutos 2024","Influenza",0,0,1,"Adult",0,0,1,0,1,0,"Low","Case-control",2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
296,"#1265","Frutos 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
296,"#1265","Frutos 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
297,"#1266","Fry 2025","RSV",0,1,0,"Immunocomp",0,0,0,1,1,1,"Low","Case-control",2025,"JAMA Netw Open",40343698,"PMC12065041","10.1001/jamanetworkopen.2025.8322","https://pmc.ncbi.nlm.nih.gov/articles/PMC12065041","Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older"
299,"#6372","Gao 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2024,"Open Forum Infectious Diseases",39220659,"PMC11365065","10.1093/ofid/ofae456","https://pmc.ncbi.nlm.nih.gov/articles/PMC11365065","Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season"
299,"#6372","Gao 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2024,"Open Forum Infectious Diseases",39220659,"PMC11365065","10.1093/ofid/ofae456","https://pmc.ncbi.nlm.nih.gov/articles/PMC11365065","Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season"
300,"#1359","Gobel 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Cohort",2025,"Vaccines (Basel)",40006661,"PMC11861871","10.3390/vaccines13020113","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861871","Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used"
300,"#1359","Gobel 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Cohort",2025,"Vaccines (Basel)",40006661,"PMC11861871","10.3390/vaccines13020113","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861871","Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used"
301,"#6336","Gaddh 2023","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2023,"TH Open",38053618,"PMC10695705","10.1055/a-2183-5269","https://pmc.ncbi.nlm.nih.gov/articles/PMC10695705","Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations"
301,"#6336","Gaddh 2023","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2023,"TH Open",38053618,"PMC10695705","10.1055/a-2183-5269","https://pmc.ncbi.nlm.nih.gov/articles/PMC10695705","Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations"
302,"#6348","Gallagher 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Otolaryngol Head Neck Surg",38822762,,"10.1002/ohn.833","https://pubmed.ncbi.nlm.nih.gov/38822762","Association of COVID-19 Vaccination With Changes in Smell and Taste"
302,"#6348","Gallagher 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Otolaryngol Head Neck Surg",38822762,,"10.1002/ohn.833","https://pubmed.ncbi.nlm.nih.gov/38822762","Association of COVID-19 Vaccination With Changes in Smell and Taste"
303,"#6361","Ganelin-Cohen 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Brain Behav",38940313,"PMC11212002","10.1002/brb3.3587","https://pmc.ncbi.nlm.nih.gov/articles/PMC11212002","The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI"
303,"#6361","Ganelin-Cohen 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Brain Behav",38940313,"PMC11212002","10.1002/brb3.3587","https://pmc.ncbi.nlm.nih.gov/articles/PMC11212002","The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI"
305,"#21702","Garrett 2025","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"High","Cohort",2025,"EClinicalMedicine",39902315,"PMC11788791","10.1016/j.eclinm.2024.103054","https://pmc.ncbi.nlm.nih.gov/articles/PMC11788791","Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study"
307,"#1336","Gharpure 2025","Influenza",0,0,1,"Immunocomp",0,0,1,1,1,1,"High","Case-control",2025,"Lancet Glob Health",39890222,,"10.1016/s2214-109x(24)00473-x","https://pubmed.ncbi.nlm.nih.gov/39890222","Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design"
308,"#14940","Giang 2024","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Can Commun Dis Rep",38655243,"PMC11037881","10.14745/ccdr.v50i12a02","https://pmc.ncbi.nlm.nih.gov/articles/PMC11037881","Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022"
309,"#21752","Giovanetti 2025","Influenza",0,0,1,"Pediatric",0,1,1,1,1,0,"Low","Observational - other",2025,"Microorganisms",40142362,"PMC11945264","10.3390/microorganisms13030469","https://pmc.ncbi.nlm.nih.gov/articles/PMC11945264","Epidemiological Transitions in Influenza Dynamics in the United States: Insights from Recent Pandemic Challenges"
309,"#21752","Giovanetti 2025","Influenza",0,0,1,"Adult",0,1,1,1,1,0,"Low","Observational - other",2025,"Microorganisms",40142362,"PMC11945264","10.3390/microorganisms13030469","https://pmc.ncbi.nlm.nih.gov/articles/PMC11945264","Epidemiological Transitions in Influenza Dynamics in the United States: Insights from Recent Pandemic Challenges"
310,"#21760","Gligorov 2025","COVID",1,0,1,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"Therapie",40090811,,"10.1016/j.therap.2025.02.007","https://pubmed.ncbi.nlm.nih.gov/40090811","Vaccines and the risk of Guillain-Barr syndrome: A French pharmacovigilance analysis"
310,"#21760","Gligorov 2025","Influenza",1,0,1,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2025,"Therapie",40090811,,"10.1016/j.therap.2025.02.007","https://pubmed.ncbi.nlm.nih.gov/40090811","Vaccines and the risk of Guillain-Barr syndrome: A French pharmacovigilance analysis"
312,"#6513","Gonen 2023","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2023,"JAMA Netw Open",37682571,"PMC10492184","10.1001/jamanetworkopen.2023.32813","https://pmc.ncbi.nlm.nih.gov/articles/PMC10492184","Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines"
312,"#6513","Gonen 2023","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2023,"JAMA Netw Open",37682571,"PMC10492184","10.1001/jamanetworkopen.2023.32813","https://pmc.ncbi.nlm.nih.gov/articles/PMC10492184","Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines"
313,"#15013","Gordon 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Skin Health Dis",38846690,"PMC11150739","10.1002/ski2.367","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150739","Exploring cutaneous lymphoproliferative disorders in the wake of COVID-19 vaccination"
313,"#15013","Gordon 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Skin Health Dis",38846690,"PMC11150739","10.1002/ski2.367","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150739","Exploring cutaneous lymphoproliferative disorders in the wake of COVID-19 vaccination"
315,"#6561","Granja Lopez 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Frontiers in Pharmacology",39175548,"PMC11338880","10.3389/fphar.2024.1376474","https://pmc.ncbi.nlm.nih.gov/articles/PMC11338880","Neurological manifestations of immune origin after COVID-19 vaccination: retrospective case study"
316,"#6597","Grima 2024","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"Low","Observational - other",2024,"Vaccine",38341288,,"10.1016/j.vaccine.2024.01.023","https://pubmed.ncbi.nlm.nih.gov/38341288","The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data"
317,"#12280","Grimaldi 2023","Influenza",0,0,1,"Immunocomp",0,0,1,1,1,1,"Low","Cohort",2023,"JAMA Neurol",37669073,"PMC10481324","10.1001/jamaneurol.2023.2968","https://pmc.ncbi.nlm.nih.gov/articles/PMC10481324","Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups"
318,"#1415","Grisanti 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2025,"Eur J Neurol",40115993,"PMC11926444","10.1111/ene.16510","https://pmc.ncbi.nlm.nih.gov/articles/PMC11926444","Neurological long COVID in the outpatient clinic: Is it so long?"
318,"#1415","Grisanti 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2025,"Eur J Neurol",40115993,"PMC11926444","10.1111/ene.16510","https://pmc.ncbi.nlm.nih.gov/articles/PMC11926444","Neurological long COVID in the outpatient clinic: Is it so long?"
321,"#6708","Hammam 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Oman Medical Journal",40196803,"PMC11973885","10.5001/omj.2024.107","https://pmc.ncbi.nlm.nih.gov/articles/PMC11973885","Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt"
322,"#6771","Hashimoto 2024","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Observational - other",2024,"Ophthalmic Epidemiol",38085757,,"10.1080/09286586.2023.2289990","https://pubmed.ncbi.nlm.nih.gov/38085757","Ocular Adverse Events After Influenza Vaccination in Older Adults: Self-Controlled Case Series Using a Large Database in Japan"
323,"#1527","Havlin 2025","RSV",0,1,0,"Immunocomp",0,0,0,0,0,1,"High","Observational - other",2025,"Am J Transplant",40169094,,"10.1016/j.ajt.2025.03.025","https://pubmed.ncbi.nlm.nih.gov/40169094","Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees"
325,"#15356","Hikichi 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Cureus",39070394,"PMC11283873","10.7759/cureus.63410","https://pmc.ncbi.nlm.nih.gov/articles/PMC11283873","Comparison of Transient and Persistent Adverse Events After COVID-19 Vaccination: A Retrospective Analysis"
327,"#6931","Minendez 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Moderate","Observational - other",2024,"Medicina (Kaunas)",38929574,"PMC11206152","10.3390/medicina60060956","https://pmc.ncbi.nlm.nih.gov/articles/PMC11206152","Anti-COVID-19 Vaccination Alters the Menstrual Cycle and Dose Accumulation Enhances the Effect"
329,"#1606","Huang 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"International Journal of Breast Cancer",39991115,"PMC11846679","10.1155/ijbc/8126974","https://pmc.ncbi.nlm.nih.gov/articles/PMC11846679","Reactive Axillary Lymphadenopathy Among Different COVID-19 Vaccines: A Retrospective Study in Breast Sonography"
330,"#1629","Hwang 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2025,"Am J Ophthalmol",39179130,,"10.1016/j.ajo.2024.08.015","https://pubmed.ncbi.nlm.nih.gov/39179130","COVID-19 Vaccination and Ocular Adverse Events: A Self-Controlled Case Series Study From the Entire South Korean Population"
330,"#1629","Hwang 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2025,"Am J Ophthalmol",39179130,,"10.1016/j.ajo.2024.08.015","https://pubmed.ncbi.nlm.nih.gov/39179130","COVID-19 Vaccination and Ocular Adverse Events: A Self-Controlled Case Series Study From the Entire South Korean Population"
331,"#1627","Hwang 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Sci Rep",39939373,"PMC11821952","10.1038/s41598-025-88713-x","https://pmc.ncbi.nlm.nih.gov/articles/PMC11821952","Global burden of vaccine-associated kidney injury using an international pharmacovigilance database"
331,"#1627","Hwang 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Sci Rep",39939373,"PMC11821952","10.1038/s41598-025-88713-x","https://pmc.ncbi.nlm.nih.gov/articles/PMC11821952","Global burden of vaccine-associated kidney injury using an international pharmacovigilance database"
334,"#1647","Ioannou 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Observational - other",2025,"Ann Intern Med",39903865,,"10.7326/annals-24-01015","https://pubmed.ncbi.nlm.nih.gov/39903865","Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation"
335,"#7078","Ip 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Nat Commun",39085208,"PMC11291640","10.1038/s41467-024-49634-x","https://pmc.ncbi.nlm.nih.gov/articles/PMC11291640","Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England"
336,"#1648","Ip 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Int J Infect Dis",39637971,,"10.1016/j.ijid.2024.107324","https://pubmed.ncbi.nlm.nih.gov/39637971","COVID-19 vaccination and cerebral small vessel disease progression-A prospective cohort study"
337,"#7105","Itamochi 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Sci Rep",39375365,"PMC11458568","10.1038/s41598-024-73004-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC11458568","COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 nave nursing home residents"
338,"#1670","Ito 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Moderate","Cohort",2025,"Vaccine",39879847,,"10.1016/j.vaccine.2025.126754","https://pubmed.ncbi.nlm.nih.gov/39879847","Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan"
339,"#12347","Jaffry 2023","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2023,"J Neuroophthalmol",37314860,,"10.1097/wno.0000000000001900","https://pubmed.ncbi.nlm.nih.gov/37314860","Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System"
339,"#12347","Jaffry 2023","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2023,"J Neuroophthalmol",37314860,,"10.1097/wno.0000000000001900","https://pubmed.ncbi.nlm.nih.gov/37314860","Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System"
340,"#7139","Jain 2024","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"Low","Cohort",2024,"eClinicalMedicine",39290640,"PMC11406334","10.1016/j.eclinm.2024.102809","https://pmc.ncbi.nlm.nih.gov/articles/PMC11406334","Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study"
340,"#7139","Jain 2024","COVID",1,0,0,"Adult",0,0,1,1,0,0,"Low","Cohort",2024,"eClinicalMedicine",39290640,"PMC11406334","10.1016/j.eclinm.2024.102809","https://pmc.ncbi.nlm.nih.gov/articles/PMC11406334","Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study"
341,"#7142","Jajou 2024","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"Low","Cohort",2024,"Vaccine",39004527,,"10.1016/j.vaccine.2024.07.031","https://pubmed.ncbi.nlm.nih.gov/39004527","GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands"
341,"#7142","Jajou 2024","COVID",1,0,0,"Adult",0,0,1,1,0,0,"Low","Cohort",2024,"Vaccine",39004527,,"10.1016/j.vaccine.2024.07.031","https://pubmed.ncbi.nlm.nih.gov/39004527","GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands"
342,"#22192","Jajou 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Br J Clin Pharmacol",40099868,"PMC12304821","10.1002/bcp.70045","https://pmc.ncbi.nlm.nih.gov/articles/PMC12304821","General practitioner consultation for postmenopausal bleeding after COVID-19 vaccination-a self-controlled cohort study"
343,"#7164","Jarrot 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Hum Vaccin Immunother",38563792,"PMC10989707","10.1080/21645515.2024.2334084","https://pmc.ncbi.nlm.nih.gov/articles/PMC10989707","Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey"
345,"#15668","Jeong 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"J Med Virol",38783823,,"10.1002/jmv.29682","https://pubmed.ncbi.nlm.nih.gov/38783823","Global and regional burden of vaccine-associated facial paralysis, 1967-2023: Findings from the WHO international pharmacovigilance database"
345,"#15668","Jeong 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"J Med Virol",38783823,,"10.1002/jmv.29682","https://pubmed.ncbi.nlm.nih.gov/38783823","Global and regional burden of vaccine-associated facial paralysis, 1967-2023: Findings from the WHO international pharmacovigilance database"
346,"#7190","Jeong 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Sci Rep",39427003,"PMC11490553","10.1038/s41598-024-74729-2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11490553","Global burden of vaccine-associated Guillain-Barr syndrome over 170 countries from 1967 to 2023"
346,"#7190","Jeong 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Sci Rep",39427003,"PMC11490553","10.1038/s41598-024-74729-2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11490553","Global burden of vaccine-associated Guillain-Barr syndrome over 170 countries from 1967 to 2023"
347,"#1712","Jeong 2025","Influenza",0,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2025,"Sci Rep",40247100,"PMC12006434","10.1038/s41598-025-98106-9","https://pmc.ncbi.nlm.nih.gov/articles/PMC12006434","Global and regional estimates of vaccine-associated herpes zoster and their related vaccines from 1969 to 2023"
347,"#1712","Jeong 2025","Influenza",0,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2025,"Sci Rep",40247100,"PMC12006434","10.1038/s41598-025-98106-9","https://pmc.ncbi.nlm.nih.gov/articles/PMC12006434","Global and regional estimates of vaccine-associated herpes zoster and their related vaccines from 1969 to 2023"
348,"#22221","Jeong 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Eur J Clin Pharmacol",40478262,,"10.1007/s00228-025-03854-2","https://pubmed.ncbi.nlm.nih.gov/40478262","Global burden of vaccine-associated Raynaud's phenomenon, 1968-2024: A comprehensive analysis of the pharmacovigilance database"
348,"#22221","Jeong 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Eur J Clin Pharmacol",40478262,,"10.1007/s00228-025-03854-2","https://pubmed.ncbi.nlm.nih.gov/40478262","Global burden of vaccine-associated Raynaud's phenomenon, 1968-2024: A comprehensive analysis of the pharmacovigilance database"
349,"#7191","Jeskowiak-Kossakowska 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Journal of Clinical Medicine",39458123,"PMC11508506","10.3390/jcm13206173","https://pmc.ncbi.nlm.nih.gov/articles/PMC11508506","Impact of Comorbidities and Skin Diseases on Post-Vaccination Reactions: A Study on COVID-19 Vaccinations in Poland"
350,"#1735","Jiang 2025","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"High","Case-control",2025,"Emerg Microbes Infect",40192342,"PMC12164376","10.1080/22221751.2025.2490531","https://pmc.ncbi.nlm.nih.gov/articles/PMC12164376","Influenza vaccine effectiveness among primary and secondary school students in Shenzhen during the 2023/24 influenza season"
352,"#1739","Jin Hsieh 2025","RSV",0,1,0,"Pregnant",1,0,0,0,0,0,"Low","Cohort",2025,"Am J Obstet Gynecol",40324666,"PMC12353535","10.1016/j.ajog.2025.04.067","https://pmc.ncbi.nlm.nih.gov/articles/PMC12353535","Investigation of Maternal Outcomes Following Respiratory Syncytial Virus Vaccination in the Third Trimester: Insights from a Real-World U.S. Electronic Health Records Database"
353,"#7241","Jirawattanadon 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Clinical and Experimental Vaccine Research",39525675,"PMC11543796","10.7774/cevr.2024.13.4.309","https://pmc.ncbi.nlm.nih.gov/articles/PMC11543796","Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination"
354,"#11951","Jobe 2025","RSV",0,1,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2025,"MMWR Morb Mortal Wkly Rep",40179043,"PMC11970723","10.15585/mmwr.mm7411a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11970723","Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus - United States, 2014-2024"
354,"#11951","Jobe 2025","RSV",0,1,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2025,"MMWR Morb Mortal Wkly Rep",40179043,"PMC11970723","10.15585/mmwr.mm7411a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11970723","Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus - United States, 2014-2024"
356,"#7297","Jung 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Nat Commun",39039113,"PMC11263712","10.1038/s41467-024-50656-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC11263712","Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study"
356,"#7297","Jung 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Nat Commun",39039113,"PMC11263712","10.1038/s41467-024-50656-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC11263712","Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study"
357,"#7327","Kalin 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2024,"J Autoimmun",39413503,,"10.1016/j.jaut.2024.103325","https://pubmed.ncbi.nlm.nih.gov/39413503","SARS-CoV-2 mRNA vaccines do not worsen autoimmunity in patients with autoimmune liver diseases"
360,"#15830","Kang 2024","COVID",1,0,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Allergy Asthma Immunol Res",39622686,"PMC11621480","10.4168/aair.2024.16.6.613","https://pmc.ncbi.nlm.nih.gov/articles/PMC11621480","Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database"
360,"#15830","Kang 2024","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Allergy Asthma Immunol Res",39622686,"PMC11621480","10.4168/aair.2024.16.6.613","https://pmc.ncbi.nlm.nih.gov/articles/PMC11621480","Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database"
361,"#7370","Karam 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"BMC Public Health",39434043,"PMC11495130","10.1186/s12889-024-20297-z","https://pmc.ncbi.nlm.nih.gov/articles/PMC11495130","Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database"
362,"#7400","Katatbeh 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Clinical and Experimental Vaccine Research",39144130,"PMC11319113","10.7774/cevr.2024.13.3.218","https://pmc.ncbi.nlm.nih.gov/articles/PMC11319113","Incidence of narcolepsy symptoms after taking COVID-19 vaccines: a Jordanian cross-sectional study"
363,"#22376","Kawai 2025","COVID",1,0,1,"Adult",0,0,0,1,1,0,"High","Cohort",2025,"J Infect Chemother",40456446,,"10.1016/j.jiac.2025.102728","https://pubmed.ncbi.nlm.nih.gov/40456446","Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season"
363,"#22376","Kawai 2025","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"High","Cohort",2025,"J Infect Chemother",40456446,,"10.1016/j.jiac.2025.102728","https://pubmed.ncbi.nlm.nih.gov/40456446","Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season"
365,"#1849","Kern 2025","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"Moderate","Observational - other",2025,"Vaccines",40006650,"PMC11860179","10.3390/vaccines13020103","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860179","Leukocyte Count in Solid Organ Transplant Recipients After SARS-CoV-2 mRNA Vaccination and Infection"
366,"#7501","Kikuchi 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2024,"Immunol Med",38189429,,"10.1080/25785826.2023.2300163","https://pubmed.ncbi.nlm.nih.gov/38189429","Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus"
370,"#7521","Kim 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"JAMA Ophthalmol",38662361,"PMC11046406","10.1001/jamaophthalmol.2024.0973","https://pmc.ncbi.nlm.nih.gov/articles/PMC11046406","COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis"
370,"#7521","Kim 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"JAMA Ophthalmol",38662361,"PMC11046406","10.1001/jamaophthalmol.2024.0973","https://pmc.ncbi.nlm.nih.gov/articles/PMC11046406","COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis"
373,"#1896","Kim 2025","COVID",1,0,0,"Pediatric",1,1,0,0,0,0,"Low","Cohort",2025,"J Korean Med Sci",40329789,"PMC12056060","10.3346/jkms.2025.40.e63","https://pmc.ncbi.nlm.nih.gov/articles/PMC12056060","Maternal Exposures to COVID-19 Vaccine and Adverse Birth Outcomes: National Population Study in Korea"
373,"#1896","Kim 2025","COVID",1,0,0,"Pregnant",1,1,0,0,0,0,"Low","Cohort",2025,"J Korean Med Sci",40329789,"PMC12056060","10.3346/jkms.2025.40.e63","https://pmc.ncbi.nlm.nih.gov/articles/PMC12056060","Maternal Exposures to COVID-19 Vaccine and Adverse Birth Outcomes: National Population Study in Korea"
374,"#1913","Kim 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Ophthalmic Epidemiol",39288331,,"10.1080/09286586.2024.2399345","https://pubmed.ncbi.nlm.nih.gov/39288331","Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study"
376,"#7564","Kirwan 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Low","Cohort",2024,"J Infect",39343245,,"10.1016/j.jinf.2024.106293","https://pubmed.ncbi.nlm.nih.gov/39343245","Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024"
377,"#1921","Kissling 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Case-control",2025,"Euro Surveill",40511473,,"10.2807/1560-7917.Es.2025.30.23.2500011","https://pubmed.ncbi.nlm.nih.gov/40511473","Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24"
377,"#1921","Kissling 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Case-control",2025,"Euro Surveill",40511473,,"10.2807/1560-7917.Es.2025.30.23.2500011","https://pubmed.ncbi.nlm.nih.gov/40511473","Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24"
378,"#1934","Ko 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Observational - other",2025,"Epidemiol Health",40340265,,"10.4178/epih.e2025024","https://pubmed.ncbi.nlm.nih.gov/40340265","Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study"
379,"#1948","Konishi 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Hum Vaccin Immunother",40555671,,"10.1080/21645515.2025.2518646","https://pubmed.ncbi.nlm.nih.gov/40555671","Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions"
380,"#16179","Kumar 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Moderate","Observational - other",2024,"Ophthalmol Sci",38827031,"PMC11141252","10.1016/j.xops.2024.100474","https://pmc.ncbi.nlm.nih.gov/articles/PMC11141252","Risk of Recurrent Noninfectious Uveitis After Coronavirus Disease 2019 Vaccination in the United States"
380,"#16179","Kumar 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Moderate","Observational - other",2024,"Ophthalmol Sci",38827031,"PMC11141252","10.1016/j.xops.2024.100474","https://pmc.ncbi.nlm.nih.gov/articles/PMC11141252","Risk of Recurrent Noninfectious Uveitis After Coronavirus Disease 2019 Vaccination in the United States"
382,"#22585","Kwaah 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,0,0,"High","Case-control",2025,"MSMR",40455969,"PMC12186818",,"https://pmc.ncbi.nlm.nih.gov/articles/PMC12186818","Mid-season vaccine effectiveness estimates for influenza: the Department of Defense Global Respiratory Pathogen Surveillance Program, 2024-2025 season"
382,"#22585","Kwaah 2025","Influenza",0,0,1,"Adult",0,0,1,1,0,0,"High","Case-control",2025,"MSMR",40455969,"PMC12186818",,"https://pmc.ncbi.nlm.nih.gov/articles/PMC12186818","Mid-season vaccine effectiveness estimates for influenza: the Department of Defense Global Respiratory Pathogen Surveillance Program, 2024-2025 season"
383,"#22595","Kyung 2025","COVID",1,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2025,"Med Princ Pract",39369714,"PMC11805550","10.1159/000541797","https://pmc.ncbi.nlm.nih.gov/articles/PMC11805550","Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database"
383,"#22595","Kyung 2025","Influenza",1,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2025,"Med Princ Pract",39369714,"PMC11805550","10.1159/000541797","https://pmc.ncbi.nlm.nih.gov/articles/PMC11805550","Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database"
383,"#22595","Kyung 2025","COVID",1,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2025,"Med Princ Pract",39369714,"PMC11805550","10.1159/000541797","https://pmc.ncbi.nlm.nih.gov/articles/PMC11805550","Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database"
383,"#22595","Kyung 2025","Influenza",1,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2025,"Med Princ Pract",39369714,"PMC11805550","10.1159/000541797","https://pmc.ncbi.nlm.nih.gov/articles/PMC11805550","Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database"
384,"#8197","Lopez-Contreras 2023","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2023,"Cirugia y Cirujanos",,,"10.24875/CIRUE.M23000425","https://doi.org/10.24875/CIRUE.M23000425","Incidence and factors associated with early and late adverse reactions after the first dose of Pfizer-BioNTech vaccine among healthcare workers"
385,"#2252","Lopez de Las Huertas 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Pharmaceuticals (Basel)",40430457,"PMC12114770","10.3390/ph18050636","https://pmc.ncbi.nlm.nih.gov/articles/PMC12114770","Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance"
385,"#2252","Lopez de Las Huertas 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Pharmaceuticals (Basel)",40430457,"PMC12114770","10.3390/ph18050636","https://pmc.ncbi.nlm.nih.gov/articles/PMC12114770","Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance"
386,"#7774","Lafleur 2024","COVID",1,0,0,"Adult",0,0,0,0,1,0,"High","Observational - other",2024,"Hum Vaccin Immunother",38953297,"PMC11221462","10.1080/21645515.2024.2368681","https://pmc.ncbi.nlm.nih.gov/articles/PMC11221462","Omission of alcohol skin cleansing and risk of adverse events in long-term care residents undergoing COVID-19 vaccination: A cohort study"
387,"#2023","Lambo 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Cohort",2025,"Infect Dis (Lond)",39226235,,"10.1080/23744235.2024.2399108","https://pubmed.ncbi.nlm.nih.gov/39226235","The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaao, the Caribbean"
387,"#2023","Lambo 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Cohort",2025,"Infect Dis (Lond)",39226235,,"10.1080/23744235.2024.2399108","https://pubmed.ncbi.nlm.nih.gov/39226235","The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaao, the Caribbean"
389,"#2033","Laniece Delaunay 2025","COVID",1,0,0,"Immunocomp",1,0,1,1,1,1,"Low","Case-control",2025,"Influenza Other Respir Viruses",40395132,"PMC12093050","10.1111/irv.70120","https://pmc.ncbi.nlm.nih.gov/articles/PMC12093050","COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network"
390,"#22655","Lauring 2025","RSV",0,1,0,"Adult",0,0,0,1,1,0,"Moderate","Observational - other",2025,"Jama",40063039,"PMC12277020","10.1001/jama.2025.1225","https://pmc.ncbi.nlm.nih.gov/articles/PMC12277020","Genomic Characterization of RSV in the US by Vaccination Status"
391,"#2043","La Verriere 2025","RSV",0,1,0,"Pediatric",0,1,1,1,1,0,"Moderate","Observational - other",2025,"Open Forum Infectious Diseases",40567998,,"10.1093/ofid/ofaf334","https://pubmed.ncbi.nlm.nih.gov/40567998","Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024"
391,"#2043","La Verriere 2025","RSV",0,1,0,"Adult",0,1,1,1,1,0,"Moderate","Observational - other",2025,"Open Forum Infectious Diseases",40567998,,"10.1093/ofid/ofaf334","https://pubmed.ncbi.nlm.nih.gov/40567998","Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024"
392,"#7881","Lee 2023","COVID",1,0,0,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2023,"BMJ Open Respir Res",38081769,"PMC10729117","10.1136/bmjresp-2023-001992","https://pmc.ncbi.nlm.nih.gov/articles/PMC10729117","Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)"
392,"#7881","Lee 2023","COVID",1,0,0,"Adult",0,1,1,1,1,0,"High","Observational - other",2023,"BMJ Open Respir Res",38081769,"PMC10729117","10.1136/bmjresp-2023-001992","https://pmc.ncbi.nlm.nih.gov/articles/PMC10729117","Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)"
393,"#7882","Lee 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Mayo Clin Proc",39093271,,"10.1016/j.mayocp.2024.03.026","https://pubmed.ncbi.nlm.nih.gov/39093271","COVID-19 Vaccination-Related Pericarditis: A Korean Nationwide Study"
393,"#7882","Lee 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Mayo Clin Proc",39093271,,"10.1016/j.mayocp.2024.03.026","https://pubmed.ncbi.nlm.nih.gov/39093271","COVID-19 Vaccination-Related Pericarditis: A Korean Nationwide Study"
394,"#16349","Lee 2024","COVID",1,0,0,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2024,"Allergy",38071735,,"10.1111/all.15968","https://pubmed.ncbi.nlm.nih.gov/38071735","Global burden of vaccine-associated anaphylaxis and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database"
394,"#16349","Lee 2024","COVID",1,0,0,"Adult",0,1,1,1,1,0,"High","Observational - other",2024,"Allergy",38071735,,"10.1111/all.15968","https://pubmed.ncbi.nlm.nih.gov/38071735","Global burden of vaccine-associated anaphylaxis and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database"
396,"#2066","Lee 2025","COVID",1,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2025,"J Med Virol",40454841,,"10.1002/jmv.70408","https://pubmed.ncbi.nlm.nih.gov/40454841","Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data"
396,"#2066","Lee 2025","Influenza",1,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2025,"J Med Virol",40454841,,"10.1002/jmv.70408","https://pubmed.ncbi.nlm.nih.gov/40454841","Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data"
396,"#2066","Lee 2025","COVID",1,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2025,"J Med Virol",40454841,,"10.1002/jmv.70408","https://pubmed.ncbi.nlm.nih.gov/40454841","Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data"
396,"#2066","Lee 2025","Influenza",1,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2025,"J Med Virol",40454841,,"10.1002/jmv.70408","https://pubmed.ncbi.nlm.nih.gov/40454841","Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data"
398,"#2076","Lee 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2025,"Vaccine",40424706,,"10.1016/j.vaccine.2025.127300","https://pubmed.ncbi.nlm.nih.gov/40424706","Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada"
399,"#2089","Lei 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2025,"Hum Vaccin Immunother",39704470,,"10.1080/21645515.2024.2435156","https://pubmed.ncbi.nlm.nih.gov/39704470","Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China"
399,"#2089","Lei 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2025,"Hum Vaccin Immunother",39704470,,"10.1080/21645515.2024.2435156","https://pubmed.ncbi.nlm.nih.gov/39704470","Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China"
400,"#7937","Leung 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2024,"Vaccines",38932322,"PMC11209536","10.3390/vaccines12060593","https://pmc.ncbi.nlm.nih.gov/articles/PMC11209536","Risk of Seizure Aggravation after COVID-19 Vaccinations in Patients with Epilepsy"
401,"#7846","Le Vu 2023","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2023,"Neurology",37788935,,"10.1212/wnl.0000000000207847","https://pubmed.ncbi.nlm.nih.gov/37788935","Risk of Guillain-Barr Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study"
401,"#7846","Le Vu 2023","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2023,"Neurology",37788935,,"10.1212/wnl.0000000000207847","https://pubmed.ncbi.nlm.nih.gov/37788935","Risk of Guillain-Barr Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study"
402,"#7847","LeVu 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2024,"Nat Commun",39232036,"PMC11374778","10.1038/s41467-024-52038-6","https://pmc.ncbi.nlm.nih.gov/articles/PMC11374778","Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis"
402,"#7847","LeVu 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Case-control",2024,"Nat Commun",39232036,"PMC11374778","10.1038/s41467-024-52038-6","https://pmc.ncbi.nlm.nih.gov/articles/PMC11374778","Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis"
403,"#7943","Levy 2024","COVID",1,0,0,"Pediatric",0,1,1,1,1,0,"Low","Observational - other",2024,"J Infect Dis",39028664,,"10.1093/infdis/jiae364","https://pubmed.ncbi.nlm.nih.gov/39028664","Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant"
403,"#7943","Levy 2024","COVID",1,0,0,"Adult",0,1,1,1,1,0,"Low","Observational - other",2024,"J Infect Dis",39028664,,"10.1093/infdis/jiae364","https://pubmed.ncbi.nlm.nih.gov/39028664","Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant"
404,"#2105","Levy 2025","RSV",0,1,0,"Immunocomp",0,0,0,0,0,1,"High","Observational - other",2025,"Vaccines",40333311,"PMC12031295","10.3390/vaccines13040398","https://pmc.ncbi.nlm.nih.gov/articles/PMC12031295","Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains"
405,"#2106","Levy 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Case-control",2025,"Front Immunol",40034704,"PMC11872700","10.3389/fimmu.2025.1470609","https://pmc.ncbi.nlm.nih.gov/articles/PMC11872700","XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants"
406,"#22737","Lewis 2025","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"Low","Case-control",2025,"J Infect Dis",40198276,,"10.1093/infdis/jiaf185","https://pubmed.ncbi.nlm.nih.gov/40198276","Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024"
407,"#7951","Lewnard 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Nat Commun",39362845,"PMC11450198","10.1038/s41467-024-52668-w","https://pmc.ncbi.nlm.nih.gov/articles/PMC11450198","Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage"
407,"#7951","Lewnard 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Nat Commun",39362845,"PMC11450198","10.1038/s41467-024-52668-w","https://pmc.ncbi.nlm.nih.gov/articles/PMC11450198","Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage"
408,"#8025","Li 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"JMIR Public Health Surveill",39008362,"PMC11287098","10.2196/51007","https://pmc.ncbi.nlm.nih.gov/articles/PMC11287098","Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis"
408,"#8025","Li 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"JMIR Public Health Surveill",39008362,"PMC11287098","10.2196/51007","https://pmc.ncbi.nlm.nih.gov/articles/PMC11287098","Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis"
410,"#32258","Li 2025","RSV",0,1,0,"Pregnant",1,0,0,0,0,0,"High","Observational - other",2025,"Prev Med Rep",40678810,"PMC12269873","10.1016/j.pmedr.2025.103150","https://pmc.ncbi.nlm.nih.gov/articles/PMC12269873","Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023-December 2024"
411,"#2165","Lim 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Observational - other",2025,"Eur J Neurol",39739424,"PMC11683473","10.1111/ene.70020","https://pmc.ncbi.nlm.nih.gov/articles/PMC11683473","The association between acute transverse myelitis and COVID-19 vaccination in Korea: Self-controlled case series study"
412,"#8092","Lin 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Malaysian Journal of Medical Sciences",38984235,"PMC11229573","10.21315/mjms2024.31.3.10","https://pmc.ncbi.nlm.nih.gov/articles/PMC11229573","Risk Factors Associated with Cutaneous Reactions Following COVID-19 Vaccine Immunisation: A Registry-Based Case-Control Study"
413,"#8103","Link-Gelles 2024","COVID",1,0,0,"Immunocomp",0,0,0,1,0,1,"Low","Case-control",2024,"MMWR Morb Mortal Wkly Rep",38547037,"PMC10986819","10.15585/mmwr.mm7312a5","https://pmc.ncbi.nlm.nih.gov/articles/PMC10986819","Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged 18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024"
414,"#2183","Link-Gelles 2025","COVID",1,0,0,"Immunocomp",0,0,0,0,0,1,"Low","Case-control",2025,"JAMA Netw Open",40560584,"PMC12199055","10.1001/jamanetworkopen.2025.17402","https://pmc.ncbi.nlm.nih.gov/articles/PMC12199055","Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults"
415,"#2182","Link-Gelles 2025","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"Low","Case-control",2025,"MMWR Morb Mortal Wkly Rep",40014628,"PMC11867580","10.15585/mmwr.mm7406a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867580","Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged 18 Years - VISION and IVY Networks, September 2024-January 2025"
418,"#2231","Lloyd 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Pharmacoepidemiol Drug Saf",40328431,,"10.1002/pds.70151","https://pubmed.ncbi.nlm.nih.gov/40328431","Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States"
418,"#2231","Lloyd 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Pharmacoepidemiol Drug Saf",40328431,,"10.1002/pds.70151","https://pubmed.ncbi.nlm.nih.gov/40328431","Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States"
419,"#2229","Lloyd 2025","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"High","Observational - other",2025,"Vaccine",40203591,,"10.1016/j.vaccine.2025.127069","https://pubmed.ncbi.nlm.nih.gov/40203591","Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older"
420,"#8201","Lophatananon 2023","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Cohort",2023,"BMC Public Health",37784088,"PMC10546661","10.1186/s12889-023-16768-4","https://pmc.ncbi.nlm.nih.gov/articles/PMC10546661","The association of herpes zoster and influenza vaccinations with the risk of developing dementia: a population-based cohort study within the UK Clinical Practice Research Datalink"
422,"#8238","Lu 2024","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Observational - other",2024,"JAMA Netw Open",39037818,"PMC11265121","10.1001/jamanetworkopen.2024.23926","https://pmc.ncbi.nlm.nih.gov/articles/PMC11265121","Stroke After Influenza Vaccines in Older Adults in the US, 2016 to 2019"
423,"#8240","Lu 2024","COVID",1,0,0,"Adult",0,0,0,0,1,0,"Low","Observational - other",2024,"Jama",38502075,"PMC10951737","10.1001/jama.2024.1059","https://pmc.ncbi.nlm.nih.gov/articles/PMC10951737","Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults"
424,"#8278","Ma 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2024,"MMWR Morb Mortal Wkly Rep",39446667,"PMC11500842","10.15585/mmwr.mm7342a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11500842","Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024"
424,"#8278","Ma 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2024,"MMWR Morb Mortal Wkly Rep",39446667,"PMC11500842","10.15585/mmwr.mm7342a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11500842","Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024"
425,"#8294","Maan 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Hepatology",38358465,,"10.1097/hep.0000000000000787","https://pubmed.ncbi.nlm.nih.gov/38358465","Extensive splanchnic vein thrombosis after SARS-CoV-2 vaccination: A Vascular Liver Disease Group (VALDIG) initiative"
426,"#8305","Machado 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Hum Vaccin Immunother",38448394,"PMC10936612","10.1080/21645515.2024.2322196","https://pmc.ncbi.nlm.nih.gov/articles/PMC10936612","Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season"
426,"#8305","Machado 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Hum Vaccin Immunother",38448394,"PMC10936612","10.1080/21645515.2024.2322196","https://pmc.ncbi.nlm.nih.gov/articles/PMC10936612","Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season"
427,"#2314","Mackenzie 2025","COVID",1,0,0,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2025,"Vaccine",39983541,,"10.1016/j.vaccine.2025.126892","https://pubmed.ncbi.nlm.nih.gov/39983541","What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA)"
427,"#2314","Mackenzie 2025","COVID",1,0,0,"Adult",0,1,1,1,1,0,"High","Observational - other",2025,"Vaccine",39983541,,"10.1016/j.vaccine.2025.126892","https://pubmed.ncbi.nlm.nih.gov/39983541","What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA)"
428,"#2316","Madhi 2025","RSV",0,1,0,"Pregnant",1,0,0,0,0,0,"Low","RCT",2025,"Obstet Gynecol",39746206,,"10.1097/aog.0000000000005817","https://pubmed.ncbi.nlm.nih.gov/39746206","Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine"
430,"#8320","Magnus 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Low","Cohort",2024,"Eur J Epidemiol",39503924,"PMC11599392","10.1007/s10654-024-01170-0","https://pmc.ncbi.nlm.nih.gov/articles/PMC11599392","Covid-19 vaccination and menstrual bleeding disturbances among women of fertile age: a Norwegian registry study"
431,"#8394","Manniche 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Medicina (Kaunas)",39202624,"PMC11356762","10.3390/medicina60081343","https://pmc.ncbi.nlm.nih.gov/articles/PMC11356762","Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden"
431,"#8394","Manniche 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Medicina (Kaunas)",39202624,"PMC11356762","10.3390/medicina60081343","https://pmc.ncbi.nlm.nih.gov/articles/PMC11356762","Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden"
432,"#8397","Mansou 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Vaccines",39772070,"PMC11680294","10.3390/vaccines12121409","https://pmc.ncbi.nlm.nih.gov/articles/PMC11680294","Reported Adverse Events Following SARS-CoV-2 Vaccinations in the Canadian Province of Alberta and Associated Risk Factors: A Retrospective Cohort Study"
432,"#8397","Mansou 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Vaccines",39772070,"PMC11680294","10.3390/vaccines12121409","https://pmc.ncbi.nlm.nih.gov/articles/PMC11680294","Reported Adverse Events Following SARS-CoV-2 Vaccinations in the Canadian Province of Alberta and Associated Risk Factors: A Retrospective Cohort Study"
433,"#16883","Mantovani 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Biomedicines",39767757,"PMC11673082","10.3390/biomedicines12122852","https://pmc.ncbi.nlm.nih.gov/articles/PMC11673082","Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study"
434,"#8432","Marron 2024","Influenza",0,0,1,"Immunocomp",1,0,1,1,1,1,"Low","Case-control",2024,"Influenza Other Respir Viruses",39623514,"PMC11611713","10.1111/irv.70023","https://pmc.ncbi.nlm.nih.gov/articles/PMC11611713","Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland"
435,"#2405","Martinez-Baz 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2025,"Int J Infect Dis",39694231,"PMC11735411","10.1016/j.ijid.2024.107364","https://pmc.ncbi.nlm.nih.gov/articles/PMC11735411","Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study"
435,"#2405","Martinez-Baz 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2025,"Int J Infect Dis",39694231,"PMC11735411","10.1016/j.ijid.2024.107364","https://pmc.ncbi.nlm.nih.gov/articles/PMC11735411","Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study"
438,"#8481","Matsuzono 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"SAGE Open Medicine",39220747,"PMC11363057","10.1177/20503121241272518","https://pmc.ncbi.nlm.nih.gov/articles/PMC11363057","Effect of COVID 19 pandemic on the neurology department hospitalization with analysis of the neurological complications secondary to COVID 19 and vaccination against COVID 19"
439,"#8492","Maurel 2024","Influenza",0,0,1,"Pediatric",0,1,1,1,1,0,"High","Case-control",2024,"Euro Surveill",38390651,,"10.2807/1560-7917.Es.2024.29.8.2400089","https://pubmed.ncbi.nlm.nih.gov/38390651","Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024"
439,"#8492","Maurel 2024","Influenza",0,0,1,"Adult",0,1,1,1,1,0,"High","Case-control",2024,"Euro Surveill",38390651,,"10.2807/1560-7917.Es.2024.29.8.2400089","https://pubmed.ncbi.nlm.nih.gov/38390651","Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024"
440,"#23153","Mayer 2025","RSV",0,1,0,"Adult",0,0,0,1,0,0,"Low","RCT",2025,"Clin Infect Dis",40464662,,"10.1093/cid/ciaf292","https://pubmed.ncbi.nlm.nih.gov/40464662","Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years"
441,"#2444","Mazarakis 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2025,"J Infect",39978439,,"10.1016/j.jinf.2025.106447","https://pubmed.ncbi.nlm.nih.gov/39978439","The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose"
442,"#8535","McLeod 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2024,"J Infect",39550007,,"10.1016/j.jinf.2024.106346","https://pubmed.ncbi.nlm.nih.gov/39550007","The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old"
443,"#17051","Memon 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Ir Med J",39555720,,,"https://pubmed.ncbi.nlm.nih.gov/39555720","Cardiac Investigations in Paediatric Patients with Chest Pain Following COVID-19 mRNA Vaccination"
445,"#8593","Mi 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Moderate","Case-control",2024,"Hum Vaccin Immunother",39208849,"PMC11364069","10.1080/21645515.2024.2394255","https://pmc.ncbi.nlm.nih.gov/articles/PMC11364069","Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study"
445,"#8593","Mi 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Moderate","Case-control",2024,"Hum Vaccin Immunother",39208849,"PMC11364069","10.1080/21645515.2024.2394255","https://pmc.ncbi.nlm.nih.gov/articles/PMC11364069","Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study"
446,"#17154","Mohamed 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Cureus",39822416,"PMC11737604","10.7759/cureus.75889","https://pmc.ncbi.nlm.nih.gov/articles/PMC11737604","Safety of COVID-19 Vaccines in Patients With Multiple Sclerosis: A Cross-Sectional Study From a Tertiary Rehabilitation Center in Saudi Arabia"
447,"#8672","Moisset 2024","COVID",1,0,0,"Immunocomp",0,0,0,0,0,1,"Low","Observational - other",2024,"Neurology",39141880,,"10.1212/wnl.0000000000209662","https://pubmed.ncbi.nlm.nih.gov/39141880","Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series"
448,"#2557","Mok 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"J Infect",39657850,,"10.1016/j.jinf.2024.106374","https://pubmed.ncbi.nlm.nih.gov/39657850","Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine"
449,"#8678","Mombelli 2024","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"Moderate","RCT",2024,"Clin Infect Dis",37584344,"PMC10810716","10.1093/cid/ciad477","https://pmc.ncbi.nlm.nih.gov/articles/PMC10810716","Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial)"
451,"#8692","Moon 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Journal of Mycology and Infection",,,"10.17966/JMI.2024.29.3.117","https://doi.org/10.17966/JMI.2024.29.3.117","Cutaneous Manifestations of COVID-19 Vaccination and COVID-19 Infection: a Questionnaire-based, Multi-center Study in Korea"
451,"#8692","Moon 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Journal of Mycology and Infection",,,"10.17966/JMI.2024.29.3.117","https://doi.org/10.17966/JMI.2024.29.3.117","Cutaneous Manifestations of COVID-19 Vaccination and COVID-19 Infection: a Questionnaire-based, Multi-center Study in Korea"
452,"#8703","Morciano 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2024,"Drug Saf",39068268,"PMC11485117","10.1007/s40264-024-01462-0","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485117","Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study"
452,"#8703","Morciano 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2024,"Drug Saf",39068268,"PMC11485117","10.1007/s40264-024-01462-0","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485117","Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study"
453,"#8718","Moro 2024","COVID",1,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Drug Saf",38411838,"PMC11646557","10.1007/s40264-024-01406-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646557","Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)"
453,"#8718","Moro 2024","Influenza",1,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Drug Saf",38411838,"PMC11646557","10.1007/s40264-024-01406-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646557","Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)"
453,"#8718","Moro 2024","COVID",1,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Drug Saf",38411838,"PMC11646557","10.1007/s40264-024-01406-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646557","Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)"
453,"#8718","Moro 2024","Influenza",1,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Drug Saf",38411838,"PMC11646557","10.1007/s40264-024-01406-8","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646557","Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)"
454,"#8735","Moscara 2023","COVID",1,0,1,"Adult",0,0,0,1,1,0,"High","Cohort",2023,"Vaccine",37544827,,"10.1016/j.vaccine.2023.07.043","https://pubmed.ncbi.nlm.nih.gov/37544827","Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study"
454,"#8735","Moscara 2023","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"High","Cohort",2023,"Vaccine",37544827,,"10.1016/j.vaccine.2023.07.043","https://pubmed.ncbi.nlm.nih.gov/37544827","Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study"
455,"#8739","Moss 2023","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2023,"Vaccines",37897026,"PMC10610948","10.3390/vaccines11101624","https://pmc.ncbi.nlm.nih.gov/articles/PMC10610948","Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 20222023 Winter Season"
455,"#8739","Moss 2023","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2023,"Vaccines",37897026,"PMC10610948","10.3390/vaccines11101624","https://pmc.ncbi.nlm.nih.gov/articles/PMC10610948","Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 20222023 Winter Season"
457,"#23354","Mukherjee 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Brain Commun",39777257,"PMC11703551","10.1093/braincomms/fcae448","https://pmc.ncbi.nlm.nih.gov/articles/PMC11703551","Vaccination prior to SARS-CoV-2 infection does not affect the neurologic manifestations of long COVID"
458,"#8796","Murdoch 2023","COVID",1,0,1,"Adult",0,0,0,1,0,0,"Low","RCT",2023,"Infectious Diseases and Therapy",37698774,"PMC10581992","10.1007/s40121-023-00863-5","https://pmc.ncbi.nlm.nih.gov/articles/PMC10581992","Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults"
458,"#8796","Murdoch 2023","Influenza",1,0,1,"Adult",0,0,0,1,0,0,"Low","RCT",2023,"Infectious Diseases and Therapy",37698774,"PMC10581992","10.1007/s40121-023-00863-5","https://pmc.ncbi.nlm.nih.gov/articles/PMC10581992","Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults"
460,"#8844","Nakafero 2024","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"Low","Observational - other",2024,"BMJ Open Gastroenterology",38897611,"PMC11200233","10.1136/bmjgast-2024-001370","https://pmc.ncbi.nlm.nih.gov/articles/PMC11200233","Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: A UK-wide study"
461,"#8848","Nakashima 2023","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"High","Observational - other",2023,"J Infect Chemother",37481070,,"10.1016/j.jiac.2023.07.008","https://pubmed.ncbi.nlm.nih.gov/37481070","Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study"
462,"#17350","Namiki 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Heliyon",39108860,"PMC11301373","10.1016/j.heliyon.2024.e34347","https://pmc.ncbi.nlm.nih.gov/articles/PMC11301373","Comparison of adverse events following the second/third dose of BNT162b2 in a medical institute in Japan"
463,"#17357","Naqid 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Cureus",39553063,"PMC11568403","10.7759/cureus.71671","https://pmc.ncbi.nlm.nih.gov/articles/PMC11568403","Evaluating the Adverse Effects and Associated Risk Factors of COVID-19 Vaccines Among Healthcare Workers: A Retrospective Study in the Duhok Province, Iraq"
464,"#2677","Nasreen 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2025,"Vaccine",40440921,,"10.1016/j.vaccine.2025.127291","https://pubmed.ncbi.nlm.nih.gov/40440921","Risk of Guillain-Barr syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study"
464,"#2677","Nasreen 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2025,"Vaccine",40440921,,"10.1016/j.vaccine.2025.127291","https://pubmed.ncbi.nlm.nih.gov/40440921","Risk of Guillain-Barr syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study"
465,"#8873","Nazar 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Eur Heart J Cardiovasc Pharmacother",39174484,,"10.1093/ehjcvp/pvae063","https://pubmed.ncbi.nlm.nih.gov/39174484","Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data"
465,"#8873","Nazar 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Eur Heart J Cardiovasc Pharmacother",39174484,,"10.1093/ehjcvp/pvae063","https://pubmed.ncbi.nlm.nih.gov/39174484","Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data"
466,"#2684","Nazar 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Sci Rep",40425703,"PMC12116907","10.1038/s41598-025-03428-3","https://pmc.ncbi.nlm.nih.gov/articles/PMC12116907","Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database"
466,"#2684","Nazar 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Sci Rep",40425703,"PMC12116907","10.1038/s41598-025-03428-3","https://pmc.ncbi.nlm.nih.gov/articles/PMC12116907","Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database"
467,"#2692","Nelli 2025","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"High","Observational - other",2025,"Vaccines",40333305,"PMC12031221","10.3390/vaccines13040392","https://pmc.ncbi.nlm.nih.gov/articles/PMC12031221","Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study"
468,"#2695","Neutel 2025","COVID",1,1,1,"Adult",0,0,0,0,1,0,"Low","RCT",2025,"Vaccines",40006705,"PMC11860858","10.3390/vaccines13020158","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860858","Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults  65 Years of Age"
468,"#2695","Neutel 2025","RSV",1,1,1,"Adult",0,0,0,0,1,0,"Low","RCT",2025,"Vaccines",40006705,"PMC11860858","10.3390/vaccines13020158","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860858","Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults  65 Years of Age"
468,"#2695","Neutel 2025","Influenza",1,1,1,"Adult",0,0,0,0,1,0,"Low","RCT",2025,"Vaccines",40006705,"PMC11860858","10.3390/vaccines13020158","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860858","Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults  65 Years of Age"
469,"#8892","Ng 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Vaccine",39454292,,"10.1016/j.vaccine.2024.126462","https://pubmed.ncbi.nlm.nih.gov/39454292","Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore"
470,"#23468","Nguyen 2025","COVID",1,0,0,"Immunocomp",1,0,0,1,1,1,"Low","Case-control",2025,"EClinicalMedicine",39726669,"PMC11669791","10.1016/j.eclinm.2024.102995","https://pmc.ncbi.nlm.nih.gov/articles/PMC11669791","Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform"
471,"#23473","Nguyen 2025","RSV",0,1,0,"Adult",0,0,0,0,1,0,"High","Observational - other",2025,"Lancet Reg Health West Pac",40092586,"PMC11910125","10.1016/j.lanwpc.2025.101506","https://pmc.ncbi.nlm.nih.gov/articles/PMC11910125","Short term safety profile of respiratory syncytial virus vaccine in adults aged  60 years in Australia"
472,"#2715","Nham 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2025,"Vaccine",40398327,,"10.1016/j.vaccine.2025.127275","https://pubmed.ncbi.nlm.nih.gov/40398327","Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months"
473,"#2742","Nong 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Osteoarthritis Cartilage",39855291,"PMC11954666","10.1016/j.joca.2024.12.010","https://pmc.ncbi.nlm.nih.gov/articles/PMC11954666","Association of COVID-19 vaccinations with osteoarthritis flares: A case-crossover study"
474,"#8955","Nunes 2024","COVID",1,0,0,"Adult",0,0,0,0,1,0,"Low","Cohort",2024,"Expert Rev Vaccines",39535047,,"10.1080/14760584.2024.2428800","https://pubmed.ncbi.nlm.nih.gov/39535047","Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR Network Study"
475,"#8961","Nv 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Cohort",2024,"Pediatr Cardiol",37294336,"PMC10251331","10.1007/s00246-023-03200-2","https://pmc.ncbi.nlm.nih.gov/articles/PMC10251331","Longitudinal Assessment of Left Ventricular Function in Patients with Myopericarditis After mRNA COVID-19 Vaccination"
477,"#2762","Obeng 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Arch Pathol Lab Med",39246098,,"10.5858/arpa.2024-0095-OA","https://pubmed.ncbi.nlm.nih.gov/39246098","Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines"
478,"#2773","Ogawa 2025","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Observational - other",2025,"Pharmacoepidemiol Drug Saf",39777941,"PMC11706699","10.1002/pds.70082","https://pmc.ncbi.nlm.nih.gov/articles/PMC11706699","Safety Assessment of Influenza Vaccination for Neurological Outcomes Among Older Adults in Japan: A Self-Controlled Case Series Study"
479,"#17515","Oh 2024","COVID",1,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2024,"Int J Rheum Dis",39171515,,"10.1111/1756-185x.15294","https://pubmed.ncbi.nlm.nih.gov/39171515","Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database"
479,"#17515","Oh 2024","Influenza",1,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2024,"Int J Rheum Dis",39171515,,"10.1111/1756-185x.15294","https://pubmed.ncbi.nlm.nih.gov/39171515","Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database"
479,"#17515","Oh 2024","COVID",1,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2024,"Int J Rheum Dis",39171515,,"10.1111/1756-185x.15294","https://pubmed.ncbi.nlm.nih.gov/39171515","Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database"
479,"#17515","Oh 2024","Influenza",1,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2024,"Int J Rheum Dis",39171515,,"10.1111/1756-185x.15294","https://pubmed.ncbi.nlm.nih.gov/39171515","Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database"
480,"#9013","Okoye 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"J Am Med Dir Assoc",39245233,,"10.1016/j.jamda.2024.105251","https://pubmed.ncbi.nlm.nih.gov/39245233","Delirium Incidence and Predictors in SARS-CoV-2 Vaccinated Residents in Long-Term Care Facilities (LTCF): Insights from the GeroCovid Vax Study"
481,"#2796","Omole 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","RCT",2025,"Vaccines",40006738,"PMC11860627","10.3390/vaccines13020192","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860627","Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults 50 Years of Age"
483,"#9334","Ptatkowska-Adamska 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Minerva Med",39392292,,"10.23736/s0026-4806.24.09379-0","https://pubmed.ncbi.nlm.nih.gov/39392292","BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy"
484,"#9105","Padilla-Pantoja 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Aesthetic Plast Surg",39046483,,"10.1007/s00266-024-04274-w","https://pubmed.ncbi.nlm.nih.gov/39046483","Temporary Delayed Hypersensitivity Reaction to Botulinum Toxin-A After COVID-19 Vaccination: A Case Series"
485,"#2845","Pakanen 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"VACCINE: X",,,"10.1016/j.jvacx.2025.100645","https://doi.org/10.1016/j.jvacx.2025.100645","COVID-19 vaccination as a rare potential etiology for cause of death after medicolegal autopsy. A Finnish nationwide study"
487,"#9151","Park 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"J Korean Med Sci",39536790,"PMC11557253","10.3346/jkms.2024.39.e309","https://pmc.ncbi.nlm.nih.gov/articles/PMC11557253","Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea"
487,"#9151","Park 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"J Korean Med Sci",39536790,"PMC11557253","10.3346/jkms.2024.39.e309","https://pmc.ncbi.nlm.nih.gov/articles/PMC11557253","Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea"
488,"#9154","Park 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Moderate","Observational - other",2024,"J Korean Med Sci",39497564,"PMC11538574","10.3346/jkms.2024.39.e274","https://pmc.ncbi.nlm.nih.gov/articles/PMC11538574","Reported Adverse Events and Associated Factors in Korean Coronavirus Disease 2019 Vaccinations"
488,"#9154","Park 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Moderate","Observational - other",2024,"J Korean Med Sci",39497564,"PMC11538574","10.3346/jkms.2024.39.e274","https://pmc.ncbi.nlm.nih.gov/articles/PMC11538574","Reported Adverse Events and Associated Factors in Korean Coronavirus Disease 2019 Vaccinations"
489,"#17692","Parveen 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Cohort",2024,"Pak J Med Sci",39092064,"PMC11255808","10.12669/pjms.40.7.8709","https://pmc.ncbi.nlm.nih.gov/articles/PMC11255808","COVID-19 vaccination and menstrual disturbances: A prospective study from Pakistan"
491,"#23715","Pasquale 2025","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Virology",40561867,,"10.1016/j.virol.2025.110613","https://pubmed.ncbi.nlm.nih.gov/40561867","Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024"
491,"#23715","Pasquale 2025","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Virology",40561867,,"10.1016/j.virol.2025.110613","https://pubmed.ncbi.nlm.nih.gov/40561867","Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024"
492,"#23729","Pathak 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"J Am Acad Dermatol",40107504,,"10.1016/j.jaad.2025.03.021","https://pubmed.ncbi.nlm.nih.gov/40107504","Vitiligo development following COVID-19 vaccination: A retrospective analysis of 128 cases using the Vaccine Adverse Events Reporting System"
492,"#23729","Pathak 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"J Am Acad Dermatol",40107504,,"10.1016/j.jaad.2025.03.021","https://pubmed.ncbi.nlm.nih.gov/40107504","Vitiligo development following COVID-19 vaccination: A retrospective analysis of 128 cases using the Vaccine Adverse Events Reporting System"
493,"#9213","Pattinson 2024","COVID",1,0,1,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"EBioMedicine",38574407,"PMC11004685","10.1016/j.ebiom.2024.105103","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004685","Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses"
493,"#9213","Pattinson 2024","Influenza",1,0,1,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"EBioMedicine",38574407,"PMC11004685","10.1016/j.ebiom.2024.105103","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004685","Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses"
493,"#9213","Pattinson 2024","COVID",1,0,1,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"EBioMedicine",38574407,"PMC11004685","10.1016/j.ebiom.2024.105103","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004685","Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses"
493,"#9213","Pattinson 2024","Influenza",1,0,1,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"EBioMedicine",38574407,"PMC11004685","10.1016/j.ebiom.2024.105103","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004685","Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses"
494,"#9227","Payne 2024","RSV",0,1,0,"Immunocomp",0,0,0,0,0,1,"Low","Case-control",2024,"Lancet",39426837,,"10.1016/s0140-6736(24)01738-0","https://pubmed.ncbi.nlm.nih.gov/39426837","Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis"
495,"#2925","Payne 2025","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"Low","Cohort",2025,"Vaccine",40184817,,"10.1016/j.vaccine.2025.127010","https://pubmed.ncbi.nlm.nih.gov/40184817","Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged 18 years with end stage kidney disease - United States, September 2023-April 2024"
496,"#9233","Peck 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Singapore Med J",39324928,,"10.4103/singaporemedj.SMJ-2023-258","https://pubmed.ncbi.nlm.nih.gov/39324928","Anaphylaxis post-COVID-19 vaccinations in Singapore"
496,"#9233","Peck 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Singapore Med J",39324928,,"10.4103/singaporemedj.SMJ-2023-258","https://pubmed.ncbi.nlm.nih.gov/39324928","Anaphylaxis post-COVID-19 vaccinations in Singapore"
497,"#9241","Pekdiker 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Immunol Res",39285049,,"10.1007/s12026-024-09540-2","https://pubmed.ncbi.nlm.nih.gov/39285049","ASIA syndrome after BNT162b2 vaccination: Is it a distinct rheumatoid arthritis phenotype?"
498,"#17803","Petr 2024","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"High","Observational - other",2024,"Transplant Direct",38769974,,"10.1097/txd.0000000000001645","https://pubmed.ncbi.nlm.nih.gov/38769974","Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study"
499,"#9319","Pinto 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Viral Immunol",39149804,,"10.1089/vim.2024.0019","https://pubmed.ncbi.nlm.nih.gov/39149804","Comparison of Adverse Events and Antibody Responses Among Different COVID-19 Vaccination Schedules"
500,"#9320","Pira 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Vaccines",39340046,"PMC11436231","10.3390/vaccines12091016","https://pmc.ncbi.nlm.nih.gov/articles/PMC11436231","COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid"
501,"#9345","Poder 2023","Influenza",0,0,1,"Adult",0,0,0,1,0,0,"Low","RCT",2023,"Vaccines",37896932,"PMC10611124","10.3390/vaccines11101528","https://pmc.ncbi.nlm.nih.gov/articles/PMC10611124","Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 5064 Years of Age"
502,"#3014","Pratt 2025","COVID",1,1,1,"Pediatric",0,1,1,1,1,0,"Low","Observational - other",2025,"APMIS",40017167,,"10.1111/apm.70010","https://pubmed.ncbi.nlm.nih.gov/40017167","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis"
502,"#3014","Pratt 2025","RSV",1,1,1,"Pediatric",0,1,1,1,1,0,"Low","Observational - other",2025,"APMIS",40017167,,"10.1111/apm.70010","https://pubmed.ncbi.nlm.nih.gov/40017167","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis"
502,"#3014","Pratt 2025","Influenza",1,1,1,"Pediatric",0,1,1,1,1,0,"Low","Observational - other",2025,"APMIS",40017167,,"10.1111/apm.70010","https://pubmed.ncbi.nlm.nih.gov/40017167","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis"
502,"#3014","Pratt 2025","COVID",1,1,1,"Adult",0,1,1,1,1,0,"Low","Observational - other",2025,"APMIS",40017167,,"10.1111/apm.70010","https://pubmed.ncbi.nlm.nih.gov/40017167","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis"
502,"#3014","Pratt 2025","RSV",1,1,1,"Adult",0,1,1,1,1,0,"Low","Observational - other",2025,"APMIS",40017167,,"10.1111/apm.70010","https://pubmed.ncbi.nlm.nih.gov/40017167","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis"
502,"#3014","Pratt 2025","Influenza",1,1,1,"Adult",0,1,1,1,1,0,"Low","Observational - other",2025,"APMIS",40017167,,"10.1111/apm.70010","https://pubmed.ncbi.nlm.nih.gov/40017167","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis"
503,"#3018","Primicerio 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"J Neurol Sci",40373476,,"10.1016/j.jns.2025.123536","https://pubmed.ncbi.nlm.nih.gov/40373476","Small fiber neuropathy following COVID-19 vaccination: A case series"
504,"#3019","Prins 2025","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"Low","Case-control",2025,"Transpl Int",40454297,"PMC12124284","10.3389/ti.2025.14187","https://pmc.ncbi.nlm.nih.gov/articles/PMC12124284","A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Influenza Among Immunocompromised Adults With a Solid Organ Transplant"
505,"#9407","Pudasaini 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2024,"Frontiers in Cardiovascular Medicine",39494234,"PMC11527644","10.3389/fcvm.2024.1435038","https://pmc.ncbi.nlm.nih.gov/articles/PMC11527644","Levels of high-sensitive troponin T and mid-regional pro-adrenomedullin after COVID-19 vaccination in vulnerable groups: monitoring cardiovascular safety of COVID-19 vaccination"
509,"#9582","Reynolds 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Vaccines (Basel)",39340003,"PMC11435866","10.3390/vaccines12090971","https://pmc.ncbi.nlm.nih.gov/articles/PMC11435866","Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia"
509,"#9582","Reynolds 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Vaccines (Basel)",39340003,"PMC11435866","10.3390/vaccines12090971","https://pmc.ncbi.nlm.nih.gov/articles/PMC11435866","Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia"
510,"#9595","Riccomi 2024","COVID",1,0,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Vaccines",38675807,"PMC11054385","10.3390/vaccines12040425","https://pmc.ncbi.nlm.nih.gov/articles/PMC11054385","Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination"
510,"#9595","Riccomi 2024","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Vaccines",38675807,"PMC11054385","10.3390/vaccines12040425","https://pmc.ncbi.nlm.nih.gov/articles/PMC11054385","Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination"
512,"#3168","Rose 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"High","Case-control",2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"High","Case-control",2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
513,"#9686","Rossier 2024","COVID",1,0,0,"Immunocomp",0,0,0,1,0,1,"High","Cohort",2024,"Ann Med",38289017,"PMC10829820","10.1080/07853890.2023.2295979","https://pmc.ncbi.nlm.nih.gov/articles/PMC10829820","SARS-CoV-2 vaccination in inflammatory bowel disease patients is not associated with flares: a retrospective single-centre Swiss study"
514,"#3178","Rouleau 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Vaccine",40344810,,"10.1016/j.vaccine.2025.127217","https://pubmed.ncbi.nlm.nih.gov/40344810","New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada"
514,"#3178","Rouleau 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Vaccine",40344810,,"10.1016/j.vaccine.2025.127217","https://pubmed.ncbi.nlm.nih.gov/40344810","New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada"
515,"#9701","Rousculp 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Moderate","Cohort",2024,"Vaccines (Basel)",39066440,"PMC11281689","10.3390/vaccines12070802","https://pmc.ncbi.nlm.nih.gov/articles/PMC11281689","Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines"
516,"#9734","Ruzafa Martinez 2024","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Cohort",2024,"Med Clin (Barc)",39414550,,"10.1016/j.medcli.2024.07.023","https://pubmed.ncbi.nlm.nih.gov/39414550","Vaccine effectiveness in patients admitted for influenza during the 2023-2024 season"
518,"#3209","Saavedra 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2025,"Vaccines",40006708,"PMC11861607","10.3390/vaccines13020161","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861607","Prevalence of Adverse Events Reported Following the First Dose of COVID-19 Vaccines in Bahia State, Brazil, from 2021 to 2022"
519,"#9763","Safrai 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Moderate","Cohort",2024,"Minerva Obstet Gynecol",36193832,,"10.23736/s2724-606x.22.05148-x","https://pubmed.ncbi.nlm.nih.gov/36193832","BNT162b2 COVID-19 vaccine does not affect fertility as explored in a pilot study of women undergoing IVF treatment"
520,"#3241","Salmaggi 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Moderate","Observational - other",2025,"Neurol Sci",39560882,,"10.1007/s10072-024-07870-5","https://pubmed.ncbi.nlm.nih.gov/39560882","Impact of COVID-19 disease and COVID-19 vaccinations on hospital admissions for neurological diseases in the Lombardia over-12 population. Data from a self-controlled case series analysis"
520,"#3241","Salmaggi 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Moderate","Observational - other",2025,"Neurol Sci",39560882,,"10.1007/s10072-024-07870-5","https://pubmed.ncbi.nlm.nih.gov/39560882","Impact of COVID-19 disease and COVID-19 vaccinations on hospital admissions for neurological diseases in the Lombardia over-12 population. Data from a self-controlled case series analysis"
521,"#24180","Sankar 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Drug Saf",40238055,"PMC12259799","10.1007/s40264-025-01547-4","https://pmc.ncbi.nlm.nih.gov/articles/PMC12259799","Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System"
521,"#24180","Sankar 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Drug Saf",40238055,"PMC12259799","10.1007/s40264-025-01547-4","https://pmc.ncbi.nlm.nih.gov/articles/PMC12259799","Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System"
524,"#18485","Semenzato 2024","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"Low","Cohort",2024,"Jama",39186694,"PMC11348078","10.1001/jama.2024.16380","https://pmc.ncbi.nlm.nih.gov/articles/PMC11348078","Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies"
524,"#18485","Semenzato 2024","COVID",1,0,0,"Adult",0,0,1,1,0,0,"Low","Cohort",2024,"Jama",39186694,"PMC11348078","10.1001/jama.2024.16380","https://pmc.ncbi.nlm.nih.gov/articles/PMC11348078","Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies"
525,"#3337","Separovic 2025","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Case-control",2025,"Euro Surveill",39885824,,"10.2807/1560-7917.Es.2025.30.4.2500059","https://pubmed.ncbi.nlm.nih.gov/39885824","Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25"
526,"#10011","Shah 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Sports Health",37946492,"PMC11195857","10.1177/19417381231208677","https://pmc.ncbi.nlm.nih.gov/articles/PMC11195857","Cardiovascular Safety of the COVID-19 Vaccine in Team USA Athletes"
526,"#10011","Shah 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Sports Health",37946492,"PMC11195857","10.1177/19417381231208677","https://pmc.ncbi.nlm.nih.gov/articles/PMC11195857","Cardiovascular Safety of the COVID-19 Vaccine in Team USA Athletes"
527,"#3351","Shaharir 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Int J Rheum Dis",39791506,,"10.1111/1756-185x.70043","https://pubmed.ncbi.nlm.nih.gov/39791506","Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study"
528,"#10032","Shani 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Vaccine",38729910,,"10.1016/j.vaccine.2024.04.097","https://pubmed.ncbi.nlm.nih.gov/38729910","The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities"
528,"#10032","Shani 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Vaccine",38729910,,"10.1016/j.vaccine.2024.04.097","https://pubmed.ncbi.nlm.nih.gov/38729910","The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities"
529,"#10041","Shapiro 2023","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"High","Observational - other",2023,"Immunity and Ageing",37644610,"PMC10463383","10.1186/s12979-023-00367-3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10463383","The intersection of biological sex and gender in adverse events following seasonal influenza vaccination in older adults"
530,"#10043","Sharff 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Vaccine",39442285,,"10.1016/j.vaccine.2024.126440","https://pubmed.ncbi.nlm.nih.gov/39442285","Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system"
531,"#10056","Shaw 2024","RSV",0,1,0,"Adult",0,0,0,0,1,0,"Low","RCT",2024,"J Infect Dis",38385566,"PMC11420773","10.1093/infdis/jiae081","https://pmc.ncbi.nlm.nih.gov/articles/PMC11420773","Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults"
532,"#10057","Shaw 2024","RSV",0,1,0,"Adult",0,0,0,1,0,0,"Low","RCT",2024,"J Infect Dis",38298125,"PMC11420805","10.1093/infdis/jiae035","https://pmc.ncbi.nlm.nih.gov/articles/PMC11420805","Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial"
533,"#24345","Shemer 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2025,"Vaccines (Basel)",40006723,"PMC11860193","10.3390/vaccines13020176","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860193","COVID-19 Vaccination and Acute Anterior Uveitis-A Case Control Study"
534,"#10083","Sher 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"J Pediatric Infect Dis Soc",38860591,"PMC11344470","10.1093/jpids/piae062","https://pmc.ncbi.nlm.nih.gov/articles/PMC11344470","Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds"
535,"#10101","Shi 2024","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Observational - other",2024,"Vaccine",38704258,,"10.1016/j.vaccine.2024.04.051","https://pubmed.ncbi.nlm.nih.gov/38704258","Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older"
536,"#18637","Shoji 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Glob Health Med",39741991,"PMC11680453","10.35772/ghm.2024.01053","https://pmc.ncbi.nlm.nih.gov/articles/PMC11680453","Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan"
537,"#10138","Shrestha 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Moderate","Cohort",2024,"Clin Infect Dis",38465901,,"10.1093/cid/ciae132","https://pubmed.ncbi.nlm.nih.gov/38465901","Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine"
539,"#3434","Silva-Afonso 2025","COVID",1,1,1,"Pediatric",0,1,0,0,1,0,"Low","Case-control",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA",40467410,,"10.1016/j.eimc.2025.03.006","https://pubmed.ncbi.nlm.nih.gov/40467410","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department"
539,"#3434","Silva-Afonso 2025","RSV",1,1,1,"Pediatric",0,1,0,0,1,0,"Low","Case-control",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA",40467410,,"10.1016/j.eimc.2025.03.006","https://pubmed.ncbi.nlm.nih.gov/40467410","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department"
539,"#3434","Silva-Afonso 2025","Influenza",1,1,1,"Pediatric",0,1,0,0,1,0,"Low","Case-control",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA",40467410,,"10.1016/j.eimc.2025.03.006","https://pubmed.ncbi.nlm.nih.gov/40467410","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department"
539,"#3434","Silva-Afonso 2025","COVID",1,1,1,"Adult",0,1,0,0,1,0,"Low","Case-control",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA",40467410,,"10.1016/j.eimc.2025.03.006","https://pubmed.ncbi.nlm.nih.gov/40467410","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department"
539,"#3434","Silva-Afonso 2025","RSV",1,1,1,"Adult",0,1,0,0,1,0,"Low","Case-control",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA",40467410,,"10.1016/j.eimc.2025.03.006","https://pubmed.ncbi.nlm.nih.gov/40467410","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department"
539,"#3434","Silva-Afonso 2025","Influenza",1,1,1,"Adult",0,1,0,0,1,0,"Low","Case-control",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA",40467410,,"10.1016/j.eimc.2025.03.006","https://pubmed.ncbi.nlm.nih.gov/40467410","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department"
541,"#10228","Skowronski 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2024,"Euro Surveill",38362622,,"10.2807/1560-7917.Es.2024.29.7.2400076","https://pubmed.ncbi.nlm.nih.gov/38362622","2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)"
541,"#10228","Skowronski 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2024,"Euro Surveill",38362622,,"10.2807/1560-7917.Es.2024.29.7.2400076","https://pubmed.ncbi.nlm.nih.gov/38362622","2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)"
542,"#10236","Slingerland 2023","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2023,"Drug Saf",37882905,,"10.1007/s40264-023-01356-7","https://pubmed.ncbi.nlm.nih.gov/37882905","The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands"
543,"#3468","Smith 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Med J Aust",39655683,,"10.5694/mja2.52557","https://pubmed.ncbi.nlm.nih.gov/39655683","Clinical phenotype of COVID-19 vaccine-associated myocarditis in Victoria, 2021-22: a cross-sectional study"
543,"#3468","Smith 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Med J Aust",39655683,,"10.5694/mja2.52557","https://pubmed.ncbi.nlm.nih.gov/39655683","Clinical phenotype of COVID-19 vaccine-associated myocarditis in Victoria, 2021-22: a cross-sectional study"
544,"#10254","Smolarchuk 2024","Influenza",0,0,1,"Immunocomp",0,0,1,1,1,1,"Low","Case-control",2024,"Euro Surveill",38214082,,"10.2807/1560-7917.Es.2024.29.2.2300709","https://pubmed.ncbi.nlm.nih.gov/38214082","Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season"
545,"#3481","Sodagari 2025","COVID",1,0,0,"Immunocomp",1,0,0,1,1,1,"High","Observational - other",2025,"Brain, Behavior, and Immunity - Health",39686920,"PMC11646749","10.1016/j.bbih.2024.100902","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646749","Examining vaccination-related adverse events in frequent neurodegenerative diseases"
546,"#10264","Soe 2024","COVID",1,0,0,"Adult",0,0,0,0,1,0,"High","Cohort",2024,"Vaccine",38714447,,"10.1016/j.vaccine.2024.04.096","https://pubmed.ncbi.nlm.nih.gov/38714447","mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network"
547,"#10367","Strid 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Obstet Gynecol",38781590,,"10.1097/aog.0000000000005615","https://pubmed.ncbi.nlm.nih.gov/38781590","Postmenopausal Bleeding After Coronavirus Disease 2019 (COVID-19) Vaccination: Vaccine Adverse Event Reporting System"
548,"#24573","Subaiea 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Front Pharmacol",40356957,"PMC12066665","10.3389/fphar.2025.1561410","https://pmc.ncbi.nlm.nih.gov/articles/PMC12066665","Charting the COVID-19 vaccination journey in Saudi Arabia: Insights into post-vaccination adverse effects and immunization dynamics"
549,"#3602","Sun 2025","Influenza",0,0,1,"Pediatric",0,1,1,1,1,0,"Moderate","Case-control",2025,"Euro Surveill",39980425,,"10.2807/1560-7917.Es.2025.30.7.2500084","https://pubmed.ncbi.nlm.nih.gov/39980425","Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season"
549,"#3602","Sun 2025","Influenza",0,0,1,"Adult",0,1,1,1,1,0,"Moderate","Case-control",2025,"Euro Surveill",39980425,,"10.2807/1560-7917.Es.2025.30.7.2500084","https://pubmed.ncbi.nlm.nih.gov/39980425","Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season"
550,"#3592","Sun 2025","COVID",1,0,0,"Immunocomp",0,0,1,1,1,1,"High","Cohort",2025,"Vaccine",39700907,,"10.1016/j.vaccine.2024.126629","https://pubmed.ncbi.nlm.nih.gov/39700907","Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States"
551,"#10420","Surie 2024","RSV",0,1,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2024,"Jama",39230920,"PMC11375516","10.1001/jama.2024.15775","https://pmc.ncbi.nlm.nih.gov/articles/PMC11375516","RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older"
553,"#10431","Swift 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Open Forum Infectious Diseases",39290777,"PMC11406745","10.1093/ofid/ofae495","https://pmc.ncbi.nlm.nih.gov/articles/PMC11406745","Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras"
553,"#10431","Swift 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Open Forum Infectious Diseases",39290777,"PMC11406745","10.1093/ofid/ofae495","https://pmc.ncbi.nlm.nih.gov/articles/PMC11406745","Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras"
554,"#3634","Takada 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"J Infect Chemother",39103148,,"10.1016/j.jiac.2024.07.025","https://pubmed.ncbi.nlm.nih.gov/39103148","SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database"
554,"#3634","Takada 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"J Infect Chemother",39103148,,"10.1016/j.jiac.2024.07.025","https://pubmed.ncbi.nlm.nih.gov/39103148","SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database"
555,"#10466","Talib 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"J Cardiovasc Magn Reson",38479457,"PMC11004989","10.1016/j.jocmr.2024.101036","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004989","Cardiovascular magnetic resonance imaging and clinical follow-up in patients with clinically suspected myocarditis after COVID-19 vaccination"
557,"#10479","Tanaka 2024","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Eur J Neurol",38117538,"PMC11236019","10.1111/ene.16172","https://pmc.ncbi.nlm.nih.gov/articles/PMC11236019","Risk of stroke within 3, 7, 14, 21 and 30 days after influenza vaccination in Alberta, Canada: A population-based study"
558,"#19001","Tani 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Cohort",2024,"Vaccine X",38699157,"PMC11063515","10.1016/j.jvacx.2024.100489","https://pmc.ncbi.nlm.nih.gov/articles/PMC11063515","Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations"
560,"#19019","Tartof 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Low","Case-control",2024,"Open Forum Infect Dis",39015348,"PMC11250225","10.1093/ofid/ofae370","https://pmc.ncbi.nlm.nih.gov/articles/PMC11250225","Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages"
561,"#10507","Tartof 2024","RSV",0,1,0,"Adult",0,0,0,0,1,0,"Low","Case-control",2024,"JAMA Netw Open",39671195,"PMC11645642","10.1001/jamanetworkopen.2024.50832","https://pmc.ncbi.nlm.nih.gov/articles/PMC11645642","Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease"
562,"#10522","Taylor 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Observational - other",2024,"MMWR Morb Mortal Wkly Rep",39361542,"PMC11449267","10.15585/mmwr.mm7339a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11449267","COVID-19-Associated Hospitalizations Among U.S. Adults Aged 18 Years - COVID-NET, 12 States, October 2023-April 2024"
564,"#10548","Testi 2024","COVID",1,0,0,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Ocul Immunol Inflamm",37315304,,"10.1080/09273948.2023.2220782","https://pubmed.ncbi.nlm.nih.gov/37315304","Ocular Inflammatory Events Following COVID-19 Vaccination in the Paediatric Population: A Multinational Case Series"
565,"#10549","Testi 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Br J Ophthalmol",38041661,,"10.1136/bjo-2023-324503","https://pubmed.ncbi.nlm.nih.gov/38041661","Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK"
565,"#10549","Testi 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Br J Ophthalmol",38041661,,"10.1136/bjo-2023-324503","https://pubmed.ncbi.nlm.nih.gov/38041661","Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK"
566,"#10550","Tetsuka 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"Moderate","Cohort",2024,"VACCINE: X",39040886,"PMC11260603","10.1016/j.jvacx.2024.100516","https://pmc.ncbi.nlm.nih.gov/articles/PMC11260603","Adverse events of COVID-19 vaccination during 20212022 suppressed by breakfast consumption and favorable sleeping habit among Japanese university students"
567,"#3688","Thanborisutkul 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Vaccines",40266198,"PMC11946013","10.3390/vaccines13030289","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946013","Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines"
567,"#3688","Thanborisutkul 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Vaccines",40266198,"PMC11946013","10.3390/vaccines13030289","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946013","Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines"
568,"#10568","Thomas 2023","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"Low","RCT",2023,"Clin Infect Dis",39219510,"PMC10724468","10.1093/cid/ciad458","https://pmc.ncbi.nlm.nih.gov/articles/PMC10724468","Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients"
569,"#10585","Tian 2024","Influenza",0,0,1,"Adult",0,0,0,1,0,0,"High","Cohort",2024,"Vaccines",39591140,"PMC11599008","10.3390/vaccines12111237","https://pmc.ncbi.nlm.nih.gov/articles/PMC11599008","Protective Impact of Influenza Vaccination on Healthcare Workers"
570,"#10617","Top 2024","COVID",1,0,0,"Immunocomp",1,0,1,1,1,1,"High","Cohort",2024,"Vaccine",39413493,,"10.1016/j.vaccine.2024.126445","https://pubmed.ncbi.nlm.nih.gov/39413493","Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study"
571,"#37186","Tursinov 2025","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2025,"Front Public Health",40672927,"PMC12263602","10.3389/fpubh.2025.1520821","https://pmc.ncbi.nlm.nih.gov/articles/PMC12263602","COVID-19 vaccination pharmacovigilance in Khojaly district, Uzbekistan: an epidemiological evaluation"
571,"#37186","Tursinov 2025","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2025,"Front Public Health",40672927,"PMC12263602","10.3389/fpubh.2025.1520821","https://pmc.ncbi.nlm.nih.gov/articles/PMC12263602","COVID-19 vaccination pharmacovigilance in Khojaly district, Uzbekistan: an epidemiological evaluation"
572,"#24824","Umezawa 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Cureus",40271323,"PMC12017381","10.7759/cureus.81085","https://pmc.ncbi.nlm.nih.gov/articles/PMC12017381","A Series of Glomerular Diseases That Developed After COVID-19 Vaccination"
573,"#3796","van Ewijk 2025","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"High","Observational - other",2025,"Vaccine X",39734394,"PMC11681879","10.1016/j.jvacx.2024.100593","https://pmc.ncbi.nlm.nih.gov/articles/PMC11681879","Innate immune response after BNT162b2 COVID-19 vaccination associates with reactogenicity"
573,"#3796","van Ewijk 2025","COVID",1,0,0,"Adult",0,0,1,1,0,0,"High","Observational - other",2025,"Vaccine X",39734394,"PMC11681879","10.1016/j.jvacx.2024.100593","https://pmc.ncbi.nlm.nih.gov/articles/PMC11681879","Innate immune response after BNT162b2 COVID-19 vaccination associates with reactogenicity"
576,"#10824","Villanueva 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Hum Vaccin Immunother",38445666,"PMC10936640","10.1080/21645515.2024.2323853","https://pmc.ncbi.nlm.nih.gov/articles/PMC10936640","Factors influencing adverse events following COVID-19 vaccination"
577,"#24912","Vita 2025","COVID",1,0,0,"Immunocomp",0,0,0,1,1,1,"High","Observational - other",2025,"Vaccines (Basel)",40266144,"PMC11946322","10.3390/vaccines13030273","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946322","COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer"
578,"#10878","Walsh 2024","RSV",0,1,0,"Adult",0,0,0,1,1,0,"Low","RCT",2024,"J Infect Dis",38606958,"PMC11481295","10.1093/infdis/jiae185","https://pmc.ncbi.nlm.nih.gov/articles/PMC11481295","Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination"
579,"#24941","Walsh 2025","RSV",0,1,0,"Adult",0,0,0,0,1,0,"High","RCT",2025,"Clin Infect Dis",39928572,,"10.1093/cid/ciaf061","https://pubmed.ncbi.nlm.nih.gov/39928572","Efficacy, Immunogenicity, and Safety of the Bivalent RSV Prefusion F (RSVpreF) Vaccine in Older Adults Over 2 RSV Seasons"
580,"#10883","Wan 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Cohort",2024,"Int J Infect Dis",38909928,,"10.1016/j.ijid.2024.107149","https://pubmed.ncbi.nlm.nih.gov/38909928","Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation"
580,"#10883","Wan 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Cohort",2024,"Int J Infect Dis",38909928,,"10.1016/j.ijid.2024.107149","https://pubmed.ncbi.nlm.nih.gov/38909928","Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation"
581,"#10952","Wang 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"Frontiers in Pharmacology",38841369,"PMC11150672","10.3389/fphar.2024.1374320","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150672","COVID-19 vaccination-related tinnitus is associated with pre-vaccination metabolic disorders"
581,"#10952","Wang 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"Frontiers in Pharmacology",38841369,"PMC11150672","10.3389/fphar.2024.1374320","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150672","COVID-19 vaccination-related tinnitus is associated with pre-vaccination metabolic disorders"
582,"#3927","Ward 2025","COVID",1,0,0,"Adult",0,0,0,0,1,0,"Low","Cohort",2025,"J Infect",40054670,,"10.1016/j.jinf.2025.106461","https://pubmed.ncbi.nlm.nih.gov/40054670","Understanding the effectiveness of the Comirnaty monovalent and bivalent vaccines during the Winter Coronavirus (COVID-19) Infection Study"
583,"#3937","Wee 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Clin Infect Dis",39657038,,"10.1093/cid/ciae598","https://pubmed.ncbi.nlm.nih.gov/39657038","Bivalent Boosters and Risk of Postacute Sequelae Following Vaccine-Breakthrough SARS-CoV-2 Omicron Infection: A Cohort Study"
584,"#12733","Werner 2023","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Cohort",2023,"BMC Med",37726711,"PMC10510262","10.1186/s12916-023-03064-6","https://pmc.ncbi.nlm.nih.gov/articles/PMC10510262","Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study"
585,"#19530","Whitaker 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Moderate","Case-control",2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
585,"#19530","Whitaker 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Moderate","Case-control",2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
587,"#40038","Wilson 2025","COVID",1,0,0,"Immunocomp",0,0,0,0,1,1,"Low","Cohort",2025,"Infect Dis Ther",39708059,,"10.1101/2025.03.27.25324770v1","https://pubmed.ncbi.nlm.nih.gov/39708059","Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Associated Hospitalizations and Medically Attended COVID-19 among adults aged  18 years in the United States"
589,"#11097","Won 2024","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Cohort",2024,"Vaccine",38641496,,"10.1016/j.vaccine.2024.03.078","https://pubmed.ncbi.nlm.nih.gov/38641496","Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly"
590,"#11107","Woo 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,0,0,"High","Observational - other",2024,"Vaccine",39241357,"PMC12136157","10.1016/j.vaccine.2024.126290","https://pmc.ncbi.nlm.nih.gov/articles/PMC12136157","Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024)"
590,"#11107","Woo 2024","Influenza",0,0,1,"Adult",0,0,1,1,0,0,"High","Observational - other",2024,"Vaccine",39241357,"PMC12136157","10.1016/j.vaccine.2024.126290","https://pmc.ncbi.nlm.nih.gov/articles/PMC12136157","Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024)"
591,"#3989","Woo 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Moderate","Observational - other",2025,"RMD Open",40295118,"PMC12039019","10.1136/rmdopen-2024-005138","https://pmc.ncbi.nlm.nih.gov/articles/PMC12039019","Risk of new-onset polymyalgia rheumatica following COVID-19 vaccination in South Korea: a self-controlled case-series study"
592,"#3999","Wu 2025","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"PLoS One",40392910,"PMC12091759","10.1371/journal.pone.0310474","https://pmc.ncbi.nlm.nih.gov/articles/PMC12091759","Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis"
593,"#11161","Xiang 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Int J Infect Dis",38701913,,"10.1016/j.ijid.2024.107080","https://pubmed.ncbi.nlm.nih.gov/38701913","Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: A study using data from the UK Biobank"
595,"#11174","Xie 2024","COVID",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Jama",38748411,"PMC11097092","10.1001/jama.2024.7395","https://pmc.ncbi.nlm.nih.gov/articles/PMC11097092","Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024"
595,"#11174","Xie 2024","Influenza",1,0,1,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Jama",38748411,"PMC11097092","10.1001/jama.2024.7395","https://pmc.ncbi.nlm.nih.gov/articles/PMC11097092","Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024"
596,"#11193","Xu 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Observational - other",2024,"JMIR Public Health Surveill",38916940,"PMC11234065","10.2196/53807","https://pmc.ncbi.nlm.nih.gov/articles/PMC11234065","Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study"
598,"#4039","Xu 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2025,"Eur Heart J",39344920,"PMC11704415","10.1093/eurheartj/ehae639","https://pmc.ncbi.nlm.nih.gov/articles/PMC11704415","Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study"
599,"#11227","Yamamoto 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2024,"Front Public Health",39139673,"PMC11320210","10.3389/fpubh.2024.1406315","https://pmc.ncbi.nlm.nih.gov/articles/PMC11320210","Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis"
600,"#4093","Yaron 2025","Influenza",0,0,1,"Immunocomp",0,0,0,0,1,1,"Low","Cohort",2025,"npj Vaccines",39788985,"PMC11718019","10.1038/s41541-025-01065-5","https://pmc.ncbi.nlm.nih.gov/articles/PMC11718019","Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations"
601,"#19817","Yechezkel 2024","COVID",1,0,1,"Immunocomp",0,0,1,1,1,1,"Moderate","Cohort",2024,"Commun Med (Lond)",39181950,"PMC11344792","10.1038/s43856-024-00588-7","https://pmc.ncbi.nlm.nih.gov/articles/PMC11344792","Comparison of physiological and clinical reactions to COVID-19 and influenza vaccination"
601,"#19817","Yechezkel 2024","Influenza",1,0,1,"Immunocomp",0,0,1,1,1,1,"Moderate","Cohort",2024,"Commun Med (Lond)",39181950,"PMC11344792","10.1038/s43856-024-00588-7","https://pmc.ncbi.nlm.nih.gov/articles/PMC11344792","Comparison of physiological and clinical reactions to COVID-19 and influenza vaccination"
602,"#11312","Yih 2024","COVID",1,0,0,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2024,"Am J Otolaryngol",39096568,"PMC11634645","10.1016/j.amjoto.2024.104448","https://pmc.ncbi.nlm.nih.gov/articles/PMC11634645","Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink"
602,"#11312","Yih 2024","COVID",1,0,0,"Adult",0,0,1,1,1,0,"Low","Observational - other",2024,"Am J Otolaryngol",39096568,"PMC11634645","10.1016/j.amjoto.2024.104448","https://pmc.ncbi.nlm.nih.gov/articles/PMC11634645","Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink"
603,"#4110","Yildirim 2025","COVID",1,0,0,"Immunocomp",0,0,0,1,0,1,"High","Observational - other",2025,"Asian Pacific Journal of Tropical Medicine",,,"10.4103/apjtm.apjtm_253_24","https://doi.org/10.4103/apjtm.apjtm_253_24","COVID-19 vaccination in patients on biologic or targeted-synthetic disease modifying anti-rheumatic drug therapy: A multi center real-world data"
604,"#11317","Yin 2024","COVID",1,0,1,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Biol Sex Differ",38890702,"PMC11184791","10.1186/s13293-024-00625-z","https://pmc.ncbi.nlm.nih.gov/articles/PMC11184791","Sex and gender differences in adverse events following influenza and COVID-19 vaccination"
604,"#11317","Yin 2024","Influenza",1,0,1,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Biol Sex Differ",38890702,"PMC11184791","10.1186/s13293-024-00625-z","https://pmc.ncbi.nlm.nih.gov/articles/PMC11184791","Sex and gender differences in adverse events following influenza and COVID-19 vaccination"
605,"#11335","Yoon 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Observational - other",2024,"Emerg Infect Dis",39378869,"PMC11521192","10.3201/eid3011.240610","https://pmc.ncbi.nlm.nih.gov/articles/PMC11521192","Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021-2022"
606,"#11344","Youngster 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Cohort",2024,"J Reprod Immunol",38677139,,"10.1016/j.jri.2024.104246","https://pubmed.ncbi.nlm.nih.gov/38677139","The effect of COVID-19 vaccination during IVF stimulation on cycle outcomes- a retrospective cohort study"
607,"#11374","Yumru Celiksoy 2024","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2024,"Bagcilar Medical Bulletin",,,"10.4274/BMB.galenos.2024.2024-03-030","https://doi.org/10.4274/BMB.galenos.2024.2024-03-030","Impact of Pfizer-BioNTech COVID-19 Vaccination on the Menstrual Cycle"
609,"#11376","Yunker 2024","Influenza",0,0,1,,0,0,0,0,0,0,"Moderate","Observational - other",2024,"J Clin Virol",39079210,"PMC11384212","10.1016/j.jcv.2024.105718","https://pmc.ncbi.nlm.nih.gov/articles/PMC11384212","Genomic evolution of influenza during the 2023-2024 season, the johns hopkins health system"
610,"#11385","Zahrani 2024","COVID",1,0,0,"Pediatric",0,0,1,1,0,0,"Low","Cohort",2024,"International Journal of General Medicine",39070223,"PMC11283260","10.2147/IJGM.S467586","https://pmc.ncbi.nlm.nih.gov/articles/PMC11283260","Occurrence of Myopericarditis Following COVID-19 Vaccination Among Adults in the Eastern Region, Saudi Arabia: A Multicenter Study"
610,"#11385","Zahrani 2024","COVID",1,0,0,"Adult",0,0,1,1,0,0,"Low","Cohort",2024,"International Journal of General Medicine",39070223,"PMC11283260","10.2147/IJGM.S467586","https://pmc.ncbi.nlm.nih.gov/articles/PMC11283260","Occurrence of Myopericarditis Following COVID-19 Vaccination Among Adults in the Eastern Region, Saudi Arabia: A Multicenter Study"
611,"#4155","Zaidi 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Front Public Health",40115337,"PMC11922928","10.3389/fpubh.2025.1420291","https://pmc.ncbi.nlm.nih.gov/articles/PMC11922928","COVID-19 vaccines side effects among the general population during the pandemic: a cross-sectional study"
612,"#4169","Zawiasa-Bryszewska 2025","Influenza",0,0,1,"Immunocomp",0,0,0,1,1,1,"Low","Cohort",2025,"Vaccines",40006735,"PMC11861709","10.3390/vaccines13020189","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861709","Safety and Efficacy of Influenza Vaccination in Kidney Graft Recipients in Late Period After Kidney Transplantation"
613,"#11414","Zeno 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2024,"MMWR Morb Mortal Wkly Rep",39361525,"PMC11449270","10.15585/mmwr.mm7339a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11449270","Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024"
613,"#11414","Zeno 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2024,"MMWR Morb Mortal Wkly Rep",39361525,"PMC11449270","10.15585/mmwr.mm7339a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11449270","Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024"
614,"#11416","Zethelius 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Cohort",2024,"Vaccine X",39474208,"PMC11513630","10.1016/j.jvacx.2024.100571","https://pmc.ncbi.nlm.nih.gov/articles/PMC11513630","Pulmonary embolism after SARS-CoV-2 vaccination"
615,"#4195","Zhang 2025","Influenza",0,0,1,"Pediatric",0,1,1,1,1,0,"Moderate","Case-control",2025,"Vaccine",39731809,,"10.1016/j.vaccine.2024.126662","https://pubmed.ncbi.nlm.nih.gov/39731809","Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season"
615,"#4195","Zhang 2025","Influenza",0,0,1,"Adult",0,1,1,1,1,0,"Moderate","Case-control",2025,"Vaccine",39731809,,"10.1016/j.vaccine.2024.126662","https://pubmed.ncbi.nlm.nih.gov/39731809","Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season"
616,"#11585","Zhu 2024","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","RCT",2024,"Vaccines",39204058,"PMC11360506","10.3390/vaccines12080935","https://pmc.ncbi.nlm.nih.gov/articles/PMC11360506","Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older"
617,"#11574","Zhu 2024","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Moderate","Case-control",2024,"MMWR Morb Mortal Wkly Rep",38421946,"PMC10907038","10.15585/mmwr.mm7308a4","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907038","Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024"
617,"#11574","Zhu 2024","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Moderate","Case-control",2024,"MMWR Morb Mortal Wkly Rep",38421946,"PMC10907038","10.15585/mmwr.mm7308a4","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907038","Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024"
618,"#25499","Zhu 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,1,0,"Low","Case-control",2025,"J Infect Dis",40359401,"PMC12353657","10.1093/infdis/jiaf248","https://pmc.ncbi.nlm.nih.gov/articles/PMC12353657","Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season"
618,"#25499","Zhu 2025","Influenza",0,0,1,"Adult",0,0,1,1,1,0,"Low","Case-control",2025,"J Infect Dis",40359401,"PMC12353657","10.1093/infdis/jiaf248","https://pmc.ncbi.nlm.nih.gov/articles/PMC12353657","Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season"
619,"#4272","Zhu 2025","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"Low","Case-control",2025,"Vaccines",39852783,"PMC11768588","10.3390/vaccines13010004","https://pmc.ncbi.nlm.nih.gov/articles/PMC11768588","Evaluation of Influenza Vaccine Effectiveness from 2021 to 2024: A Guangdong-Based Test-Negative CaseControl Study"
620,"#11603","Zornoza Moreno 2024","Influenza",0,0,1,"Pediatric",0,0,1,0,0,0,"High","Observational - other",2024,"Influenza Other Respir Viruses",39031876,"PMC11190946","10.1111/irv.13331","https://pmc.ncbi.nlm.nih.gov/articles/PMC11190946","Adverse Effects Related to Paediatric Influenza Vaccination and Its Influence on Vaccination Acceptability. The FLUTETRA Study: A Survey Conducted in the Region of Murcia, Spain"
621,"#32816","Ma 2024","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Case-control",2024,"Clin Infect Dis",39107255,,"10.1093/cid/ciae405","https://pubmed.ncbi.nlm.nih.gov/39107255","Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024"
623,"#38920","Rogers 2024","COVID",1,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"International Journal of Innovative Research in Medical Science",,,"10.23958/ijirms/vol09-i11/1982","https://doi.org/10.23958/ijirms/vol09-i11/1982","COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes"
623,"#38920","Rogers 2024","Influenza",1,0,1,"Pediatric",0,0,1,1,1,0,"High","Observational - other",2024,"International Journal of Innovative Research in Medical Science",,,"10.23958/ijirms/vol09-i11/1982","https://doi.org/10.23958/ijirms/vol09-i11/1982","COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes"
623,"#38920","Rogers 2024","COVID",1,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"International Journal of Innovative Research in Medical Science",,,"10.23958/ijirms/vol09-i11/1982","https://doi.org/10.23958/ijirms/vol09-i11/1982","COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes"
623,"#38920","Rogers 2024","Influenza",1,0,1,"Adult",0,0,1,1,1,0,"High","Observational - other",2024,"International Journal of Innovative Research in Medical Science",,,"10.23958/ijirms/vol09-i11/1982","https://doi.org/10.23958/ijirms/vol09-i11/1982","COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes"
627,"#38977","Guerrero-Del-Cueto 2025","RSV",0,1,0,"Pediatric",0,1,1,0,0,0,"Low","Case-control",2025,"Pediatr Pulmonol",40662491,"PMC12261432","10.1002/ppul.71059","https://pmc.ncbi.nlm.nih.gov/articles/PMC12261432","Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital"
628,"#38986","Mutter 2025","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"Low","Cohort",2025,"Sci Rep",40634642,"PMC12241609","10.1038/s41598-025-10633-7","https://pmc.ncbi.nlm.nih.gov/articles/PMC12241609","Association between influenza vaccine effectiveness and chronic diseases among older adults with dementia"
630,"#39217","Popham 2025","RSV",0,1,0,"Adult",0,0,0,0,1,0,"High","Cohort",2025,"J Am Med Dir Assoc",40651496,,"10.1016/j.jamda.2025.105760","https://pubmed.ncbi.nlm.nih.gov/40651496","Disproportionate Impact of Respiratory Syncytial Virus (RSV) Among Older Adults in Long-Term Care Settings"
631,"#39260","Reeves 2025","Influenza",0,0,1,"Adult",1,0,0,1,0,0,"Low","Case-control",2025,"Vaccine",40660660,"PMC12305427","10.1016/j.vaccine.2025.127483","https://pmc.ncbi.nlm.nih.gov/articles/PMC12305427","Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age"
631,"#39260","Reeves 2025","Influenza",0,0,1,"Pregnant",1,0,0,1,0,0,"Low","Case-control",2025,"Vaccine",40660660,"PMC12305427","10.1016/j.vaccine.2025.127483","https://pmc.ncbi.nlm.nih.gov/articles/PMC12305427","Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age"
632,"#39262","Nguyen 2025","Influenza",0,0,1,"Pediatric",0,0,1,1,0,0,"Low","Case-control",2025,"J Pediatric Infect Dis Soc",40736196,"PMC12392406","10.1093/jpids/piaf069","https://pmc.ncbi.nlm.nih.gov/articles/PMC12392406","Effectiveness of cell culture-based influenza vaccine, 2023-2024"
632,"#39262","Nguyen 2025","Influenza",0,0,1,"Adult",0,0,1,1,0,0,"Low","Case-control",2025,"J Pediatric Infect Dis Soc",40736196,"PMC12392406","10.1093/jpids/piaf069","https://pmc.ncbi.nlm.nih.gov/articles/PMC12392406","Effectiveness of cell culture-based influenza vaccine, 2023-2024"
633,"#39341","Pan 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"Low","Observational - other",2025,"Nat Commun",40664645,"PMC12264068","10.1038/s41467-025-61613-4","https://pmc.ncbi.nlm.nih.gov/articles/PMC12264068","Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study"
634,"#39349","Sumer 2025","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Observational - other",2025,"Ophthalmic Epidemiol",40658089,,"10.1080/09286586.2025.2522724","https://pubmed.ncbi.nlm.nih.gov/40658089","Evaluation of the Effects of mRNA-COVID 19 Vaccines on Corneal Endothelium"
635,"#39405","Jeong 2025","Influenza",0,0,1,"Pediatric",0,1,1,1,1,0,"High","Observational - other",2025,"Sci Rep",40592905,"PMC12215190","10.1038/s41598-025-04049-6","https://pmc.ncbi.nlm.nih.gov/articles/PMC12215190","Global estimates of vaccine-associated narcolepsy from 1967 to 2023"
635,"#39405","Jeong 2025","Influenza",0,0,1,"Adult",0,1,1,1,1,0,"High","Observational - other",2025,"Sci Rep",40592905,"PMC12215190","10.1038/s41598-025-04049-6","https://pmc.ncbi.nlm.nih.gov/articles/PMC12215190","Global estimates of vaccine-associated narcolepsy from 1967 to 2023"
636,"#39547","Silverman 2025","Influenza",0,0,1,"Pediatric",0,1,1,0,0,0,"High","Observational - other",2025,"Jama",40736730,"PMC12311823","10.1001/jama.2025.11534","https://pmc.ncbi.nlm.nih.gov/articles/PMC12311823","Influenza-Associated Acute Necrotizing Encephalopathy in US Children"
637,"#39722","Omole 2025","Influenza",0,0,1,"Adult",0,0,0,1,1,0,"Low","RCT",2025,"Vaccine",40714528,,"10.1016/j.vaccine.2025.127514","https://pubmed.ncbi.nlm.nih.gov/40714528","A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50years of age or older"
638,"#39863","Diya 2025","COVID",1,0,0,"Adult",0,0,0,1,1,0,"High","Observational - other",2025,"Infect Dis Ther",40591130,"PMC12339817","10.1007/s40121-025-01185-4","https://pmc.ncbi.nlm.nih.gov/articles/PMC12339817","Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial"
639,"#39866","Prabhu 2025","COVID",1,0,0,"Adult",0,0,0,1,0,0,"High","Cohort",2025,"BMC Infect Dis",40624462,"PMC12232647","10.1186/s12879-025-11254-1","https://pmc.ncbi.nlm.nih.gov/articles/PMC12232647","Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia"
640,"#39867","Li 2025","Influenza",0,0,1,"Adult",0,0,0,0,1,0,"High","Observational - other",2025,"Hum Vaccin Immunother",40641250,"PMC12258169","10.1080/21645515.2025.2525603","https://pmc.ncbi.nlm.nih.gov/articles/PMC12258169","The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024"
643,"#39963","Xu 2025","COVID",1,0,1,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2025,"Vaccine",40716143,,"10.1016/j.vaccine.2025.127548","https://pubmed.ncbi.nlm.nih.gov/40716143","Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study"
643,"#39963","Xu 2025","Influenza",1,0,1,"Pediatric",0,0,1,1,1,0,"Low","Observational - other",2025,"Vaccine",40716143,,"10.1016/j.vaccine.2025.127548","https://pubmed.ncbi.nlm.nih.gov/40716143","Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study"
643,"#39963","Xu 2025","COVID",1,0,1,"Adult",0,0,1,1,1,0,"Low","Observational - other",2025,"Vaccine",40716143,,"10.1016/j.vaccine.2025.127548","https://pubmed.ncbi.nlm.nih.gov/40716143","Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study"
643,"#39963","Xu 2025","Influenza",1,0,1,"Adult",0,0,1,1,1,0,"Low","Observational - other",2025,"Vaccine",40716143,,"10.1016/j.vaccine.2025.127548","https://pubmed.ncbi.nlm.nih.gov/40716143","Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study"
644,"#485","Blauvelt 2025","RSV",0,1,0,"Pregnant",1,0,0,0,0,0,"Low","Case-control",2025,"JAMA Netw Open",39969879,"PMC11840647","10.1001/jamanetworkopen.2024.60735","https://pmc.ncbi.nlm.nih.gov/articles/PMC11840647","Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates"
645,"#40039","Jabagi 2025","RSV",0,1,0,"Pediatric",0,1,0,0,0,0,"Low","Cohort",2025,"NEJM evidence",39998305,,"10.1056/EVIDoa2400275","https://pubmed.ncbi.nlm.nih.gov/39998305","Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants."
